

PCT

09/14/98

09155003, 091498

390 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER ACY-33261
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/155003
INTERNATIONAL APPLICATION NO. PCT/ES97/00059	INTERNATIONAL FILING DATE March 12, 1997	PRIORITY DATE CLAIMED March 14, 1996
TITLE OF INVENTION VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES		
APPLICANT(S) FOR DO/EO/US SANCHEZ, ET AL		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 		
Items 13 to 18 below concern document(s) or information included:		
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. <input type="checkbox"/> A substitute specification. 17. <input type="checkbox"/> A change of power of attorney and/or address letter. 18. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 19. <input type="checkbox"/> Other items or information: 		
<p align="center">CERTIFICATION UNDER 37 CFR 1.10</p> <p>I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EM165270319US addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231,</p> <p><i>September 14, 1998</i> Date</p> <p><i>Brenda P. Smith</i> Brenda P. Smith</p>		

APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/ES97/00059

ACY-33261

The following fees are submitted..

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☒ Search Report has been prepared by the EPO or JPO **\$930.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) **\$720.00**
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) **\$790.00**
- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$1,070.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) **\$98.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$930.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	19 - 20 =	0	x \$22.00
Independent claims	3 - 3 =	0	x \$82.00

\$0.00**\$0.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$930.00**Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐**\$0.00****SUBTOTAL =****\$930.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).**\$0.00****TOTAL NATIONAL FEE =****\$930.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐**\$0.00****TOTAL FEES ENCLOSED =****\$930.00**

Amount to be refunded	\$
charged	\$

☐ A check in the amount of _____ to cover the above fees is enclosed.☒ Please charge my Deposit Account No. **01-1300** in the amount of **\$930.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **01-1300** A duplicate copy of this sheet is enclosed.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

MS. MILAGROS A. CEPEDA
PATENT/LAW DEPARTMENT
AMERICAN HOME PRODUCTS CORPORATION
ONE CAMPUS DRIVE
PARSIPPANY, NEW JERSEY 07054

SIGNATURE

Milagros A. Cepeda

NAME

33,365

REGISTRATION NUMBER

DATE

PTO/PCT Rec'd 14 SEP 1998

09/155003

Docket No ACY-33261
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sanchez, et. al

Serial No.: Based on PCT/ES97/00059 Filed March 12, 1997

Group No.:

Filed:

Examiner:

For: VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL
GENOMES AND THEIR USE IN THE FORMULATION OF
VACCINES.

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to calculating the filing fee, please enter the following Preliminary Amendment.

The Commissioner is hereby authorized to charge any additional fees required by this paper, including the enclosed documents, and during the entire pendency of this application and to credit any excess amounts paid to Deposit Account No. 01-1300, on behalf of American Cyanamid. This letter is submitted in triplicate for ease of use by PTO and specifically, the Deposit Account Branch.

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EM165270319US addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231,

September 14, 1998
Date

Brenda P. Smith
Brenda P. Smith

IN THE CLAIMS:

Delete claims 1 - 45 and replace them with the following claims 46 - 64:

46. An expression vector, comprising of antigens capable of inducing systemic and secretory immune responses against said infectious agents having tropism for mucoses, or antibodies which confer protection against said infectious agents, said antigens or antibodies being presented in the gastrointestinal and respiratory tracts of animals treated with a recombinant expression system comprising said expression vector, characterized by:

- (a) a defective viral genome derived from the porcine transmissible gastroenteritis virus (TGEV), or its corresponding complementary DNA (cDNA), comprising the TGEV replicase recognition signals located on end 3' and 5' and, at least, a promoter, and
- (b) at least, one DNA sequence coding for a product elected from the group consisting of:

- (i) an antigen capable of inducing a systemic and secretory response against an infectious agent having tropism for mucoses, and
- (ii) an antibody which confers protection against said infectious agent, said DNA sequence being operatively linked to, at least, a promoter which is present in said defective viral genome derived from TGEV.

47. The vector according to claim 46, wherein said defective viral genome derived from TGEV or its corresponding cDNA, further comprises the complete sequence coding for the TGEV replicase.

48. The vector according to claim 46, comprising more than one DNA sequence, each one coding for a different antigen capable of inducing a systemic and secretory response against an infectious agent having tropism for mucoses.

49. The vector according to claim 46, comprising more than one DNA sequence, each one coding for a different antibody that confers protection against an infectious agent having tropism for mucoses.

20250904 15:00:00

50. A recombinant expression system for expressing antigens capable of inducing systemic and secretory immune responses against infectious agents having tropism for mucoses, or antibodies which confer protection against said infectious agents, said antigens or antibodies being presented in the gastrointestinal and respiratory tracts of animals treated with said recombinant expression system, comprising:

- (a) an expression vector of antigens capable of inducing systemic and secretory immune responses against infectious agents having tropism for mucoses, or antibodies which confer protection against said infectious agents, and
- (b) a helper virus.

51. The recombinant expression system according to claim 50, wherein said vector comprises more than one DNA sequence, each one coding for a different antigen capable of inducing a systemic and secretory response against an infectious agent having tropism for mucoses.

52. The recombinant expression system according to claim 51, comprising different expression vectors, each one containing a different DNA sequence coding for a different antigen capable of inducing a systemic and secretory response against infectious agents having tropism for mucoses.

53. The recombinant expression system according to claim 50, wherein said vector comprises more than one DNA sequence, each one coding for a different antibody which confers protection against an infectious agent having tropism for mucoses.

54. The recombinant expression system according to claim 52, comprising different expression vectors according to claim 1, each one containing a different DNA sequence coding for a different antibody which confer protection against different infectious agents having tropism for mucoses.

55. The recombinant expression system according to claim 50, wherein said helper virus provides the functional and structural proteins for the replication and encapsidation of the defective genome derived from TGEV.

56. The recombinant expression system according to claim 50, wherein said helper virus provides the functional and structural proteins for the encapsidation of the defective genome derived from TGEV.

57. A vaccine for protecting animals against an infectious agent having tropism for mucoses, comprising

(a) a suitable quantity of a recombinant expression system for expressing antigens capable of inducing systematic and secretory immune responses against infectious agents having tropism for mucoses, or antibodies which confer protection against said infectious agents, said antigens or antibodies being presented in the gastrointestinal and respiratory tracts of animals treated with said recombinant expression system, comprising:

(i) an expression vector of antigens capable of inducing systemic and secretory immune responses against infectious agents having tropism for mucoses, or antibodies which confer protection against said infectious agents, and

(ii) a helper virus,

(b) with a pharmaceutically acceptable excipient.

58. A vaccine according to claim 57, for protecting pigs against infectious agents having tropism for mucoses, comprising:

(a) a recombinant expression system selected from the group consisting of:

(i) a recombinant expression system comprising at least one expression vector containing at least one DNA sequence coding for an antigen of a porcine pathogen having tropism for mucoses;

(ii) a recombinant expression system comprising an expression vector containing more than one DNA sequence, each one coding for an antigen of a different porcine pathogen having tropism for mucoses; and

(iii) a recombinant expression system comprising different expression vectors, each one containing at least a DNA sequence coding for an antigen of a porcine pathogen having tropism for mucoses; and

(b) a porcine coronavirus as a helper virus.

091503-091498

59. A vaccine according to claim 58, wherein said porcine pathogen is selected from the group consisting of *Actinobacillus suis*, *Actinobacillus pleuropneumoniae*, *Haemophilus parasuis*, Porcine parvovirus, *Leptospira*, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Pasteurella Multocida*, *Bordetella bronchiseptica*, *Clostridium* sp., *Serpulina hyodysenteriae*, *Mycoplasma hyopneumoniae*, porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus, rotavirus, or against the pathogens causative of porcine reproductive and respiratory syndrome, Aujeszky's disease (pseudorabies), swine influenza or transmissible gastroenteritis and the etiologic agents of atrophic rhinitis and proliferative ileitis.

60. A vaccine according to claim 57, for protecting dogs against canine infectious agents having tropism for mucoses, comprising:

- (a) a recombinant expression system selected from the group consisting of:
 - (i) a recombinant expression system comprising at least one expression vector containing at least one DNA sequence coding for an antigen of a canine pathogen having tropism for mucoses;
 - (ii) a recombinant expression system comprising an expression vector containing more than one DNA sequence, each one coding for an antigen of a different canine pathogen having tropism for mucoses; and
 - (iii) a recombinant expression system comprising different expression vectors, each one containing at least DNA sequence coding for an antigen of a canine pathogen having tropism for mucoses; and
- (b) a helper virus selected from the group consisting of a canine coronavirus and a recombinant porcine coronavirus expressing the envelope protein which is recognized by the specified cell-surface receptors on canine target cells.

61. A vaccine according to claim 60, wherein said canine pathogen is selected from the group consisting of: canine herpesviruses, canine adenovirus types 1 and 2, canine parvovirus types 1 and 2, canine reovirus, canine rotavirus, canine coronavirus, canine parainfluenza virus, canine influenza virus, rabies virus, retrovirus and canine calicivirus.

62. A vaccine according to claim 57, for protecting cats against feline infectious agents having tropism for mucoses, comprising:

(a) a recombinant expression system selected from the group consisting of:

(i) a recombinant expression system comprising at least one expression vector containing at least one DNA sequence coding for an antigen of a feline pathogen having tropism for mucoses;

(ii) a recombinant expression system comprising an expression vector containing more than one DNA sequence, each one coding for an antigen of a different feline pathogen having tropism for mucoses; and

(iii) a recombinant expression system comprising different expression vectors, each one containing at least a DNA sequence coding for an antigen of a feline pathogen having tropism for mucoses; and

(b) a helper virus selected from the group consisting of a feline coronavirus and a recombinant porcine coronavirus expressing the envelope protein which is recognized by the specific cell-surface receptors on feline target cells.

63. A vaccine according to claim 62, wherein said feline pathogen is selected from the group consisting of feline calicivirus, feline immunodeficiency virus, feline herpesviruses, feline panleukopenia virus, feline reovirus, feline coronavirus, feline infectious peritonitis virus, rabies virus, feline Chlamydia psittaci and feline leukemia virus.

64. A vaccine according to claim 57, for protecting pigs against porcine transmissible gastroenteritis virus (TGEV), wherein the recombinant expression system comprises at least one expression vector containing at least a DNA sequence coding for the monoclonal antibody identified as 6A.C3 capable of neutralizing TGEV.

REMARKS

Applicants have amended the claims in order to more clearly define the invention. No new matter has been added.

This application is now ready for examination. Favorable treatment is respectfully solicited.

Respectfully submitted,



Milagros A. Cepeda
Reg. No. 33, 365

American Home Products Corporation
Patent Law Department
One Campus Drive
Parsippany, New Jersey 07054
(201)683-2124

2025 OCT 16 10 54 AM '60

VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES

5 The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses. The defective viral genome comprises the parental virus genome having viral replicase recognition signals located on ends 3' and 5' further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication. These
10 vectors are suitable for the forming of a recombinant system comprising (a) the aforesaid expression vector, and (b) a helper virus which supplies functional and structural proteins for the replication and encapsidation of the defective genome. This system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of various animal species, especially pigs, dogs and cats.

15 FIELD OF THE INVENTION

This invention relates to a number of vectors based on recombinant defective virus genomes expressing antigens suitable for the induction of systemic and secretory immune responses for the prevention of infections in the mucosae, and to their use with
20 vaccinal purposes together with a suitable helper virus.

25 BACKGROUND OF THE INVENTION

The attainment of recombinant proteins using expression vectors is a well-known fact. In general, prokaryotic and yeast expression systems are highly efficacious and easy to use, whereas the expression systems used containing superior eukaryotic cells present a number of drawbacks relative to low protein production levels and limitations in the host range. Of the existing expression systems for superior eukaryotic cells, baculovirus-based
30 vectors are the most efficacious in terms of protein production. However, they can only be used in insect cells that, as is known, glycosilate proteins differently from the way animal cells do. In addition, the construction of the recombinant virus takes place through a homologous recombination, which is a laborious technique, especially when numerous genetic variants have to be analyzed.

35 On the other hand, vectors based on DNA viruses suitable for heterologous gene expression are known. However, the use of DNA-based vectors presents numerous drawbacks for, as they replicate in the nucleus of the host cell and can become integrated in the genome, they are therefore not reliable. On the contrary, the use of RNA-based vectors overcomes the drawbacks associated with the use of DNA viruses because, since they replicate not in the genome of the host cell but in the cytoplasm, replication takes place via RNA and not via DNA, and the possibilities of integration in the genome are very
40 low, making the vectors based on these RNA viruses more reliable.

Also well-known are defective interfering particles (DI) containing the virion capsid and a defective genome, which are deletion subgenomic mutants mostly generated from infectious viral genomes by a replication error. In general, the term "DI particle" refers to defective viruses lacking a region of the RNA or DNA genome, containing the proteins
45 and antigens of the virus, requiring co-infection of the infectious parental virus (helper virus) for replication and which specifically interfere with the homologous helper virus, as they replicate at its expense [Huang and Baltimore, Nature, 226, 325-327 (1970)]. DI genomes arise from genome reorganizations as a result of shifts of the RNA polymerase from one RNA template to another or from one segment of an RNA template to another
50 segment of the same molecule. These DI genomes, once they have been generated, self

amplify at the expense of the parental genome or the amplifying virus coding for the proteins involved in replication and encapsidation and which has to compete with defective genomes for such products.

DI particles have been obtained and characterized from some coronaviruses, such as the murine hepatitis virus (MHV), infectious bronchitis virus (IBV), and bovine coronavirus (BCV), although DI particles derived from porcine transmissible gastroenteritis virus (TGEV) have not been described. One of the MHV natural DI particles has been used as the basis for the development of an expression vector in which the exogenous gene is inserted under the control of an internal promoter transcription sequence [Lin and Lai, J. Virol., 6110-6118, Oct. (1993)].

Generally, known heterologous gene expression vectors based on DI particles have some drawbacks related with their species and target organ specificity and their limited capacity for cloning, that limit their possibilities of use, both in basic research and in research applied to the development of such vectors for therapeutical purposes, including vaccines.

Consequently, there is still need of heterologous gene expression vectors that may successfully overcome the mentioned drawbacks. Specifically, it would be highly advantageous to have available some heterologous gene expression vectors with a high level of safety and cloning capacity and which could be designed so that their species specificity and tropism might be easily controlled.

The present invention provides a solution to the existing problem, comprising a vector based on a recombinant defective viral genome expressing antigens suitable for the induction of an immune response and for the prevention of infections caused by different infectious agents in various animal species. The heterologous gene expression vectors (or DNA sequences) provided by this invention have a high level of safety, as well as high cloning capacity, and may be designed so that their species specificity and tropism may easily be controlled, making such vectors suitable for the formulation of vaccines capable of conferring protection against infections caused by the different infectious agents in various animal species.

Therefore, an object of the present invention is a vector based on a recombinant defective viral genome expressing at least one antigen suitable for the induction of immune response —specifically, a systemic and secretory immune response against infectious agents in various animal species—, or an antibody providing protection against an infectious agent provided with a high level of safety and cloning capacity, and which may be designed so that its species specificity and tropism may be easily controlled.

The defective viral genome which serves as a basis for the construction of the said vector is also an additional objective of this invention.

Another additional object of this invention is a recombinant expression system of heterologous proteins comprising (a) the vector described above and (b) a helper virus that will provide the proteins involved in the replication and encapsidation of the recombinant defective viral genome.

Another additional objective of this invention is vaccines capable of inducing protection against infections caused by different infectious agents in various animal species, comprising the recombinant system described above, together with a pharmaceutically acceptable excipient. These vectors can be uni-, or multivalent, depending on whether the expression vectors present in the recombinant system express one, or more antigens capable of inducing an immune response against one, or more

infectious agents, or one or more antibodies providing protection against one or more infectious agents.

Other objects provided by this invention comprise a method for the immunization of animals, consisting of the administration of the said recombinant system or vaccine, as well as a method for the protection of newborn animals from infectious agents that infect the mentioned species.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the structure of TGEV. The virion is a spherical particle consisting of a lipidic envelope in whose interior is a single-chain, positive-polarity RNA molecule of 28.5 kilobases (kb). This RNA is associated to an N protein forming the nucleocapsid. M and sM structural proteins are included in the membrane. Protein S groups itself into trimers, and is anchored on the external part of the envelope forming the peplomers.

Figure 2 shows the genomic organization of the four sequenced coronaviruses: MHV, IBV, HCV229E (human coronavirus 229E) and TGEV. The open reading frames coding for each protein are shown to scale. In each genome, the beginning of the RNAs expressing each virus is indicated with an arrow. The number of messenger RNAs (mRNA) expressed by viruses MHV or TGEV may vary depending on the viral strain. In this outline, the TGEV arrows correspond to the mRNAs expressed by strain THER-1. The mRNAs are 3'-coterminal and are numbered in decreasing size order.

Figure 3 shows the expression of the TGEV genome, strain THER-1. The disposition of the open reading frames (ORF) in the genome is indicated: Pol, polymerase; S, sM, M and N, structural proteins; nsp 3a, 3b and 7, non-structural proteins (protein 3b is not produced with this virus). The genome is transcribed in an RNA of equal length but of negative polarity (-) that will serve as a template for the synthesis of the 7 mRNAs (1 to 7). In each mRNA are represented the common sequence, leader, of the 5' end (square), the polyadenine section at the 3' end and the zone which is translated in each one of them (thick lines).

Figure 4 shows the evolution of the titer of TGEV THER-1 (A) and PUR46-mar 1CC12 (B) isolates with the passage number at high multiplicity of infection (m.o.i.) in ST cells.

Figure 5 shows the results of the electrophoretic analysis of the RNAs produced in ST cells infected with THER-1 virus passaged 46 times at high m.o.i. The passage number is indicated above each lane and the bars to the left indicate the position of the molecular weight markers (genomic RNA of the TGEV and GibcoBRL markers), expressed in kb. The bars to the right indicate the TGEV mRNAs and the defective interfering (DI) RNAs. NI, not infected.

Figure 6 shows the results of the Northern-blot assay of the RNA of ST cells infected with the THER-1p35 virus.

Figure 7 shows the results of the Northern-blot assay of the RNA proceeding from diluted passages of the THER-1-STp41 virus in ST cells.

Figure 8 shows the effect of the cell line change on the propagation of defective RNAs A, B and C. Virus THER-1-STp46 was passaged ten times undiluted in IPEC (intestinal pig epithelium cells), and five times in PM (porcine macrophage) cells. Figures 8A and 8B: evolution of the virus titer with the number of the passage in IPEC and PM, respectively. Figure 8C: analysis of the RNA of ST cells infected with virus from passages 1 and 10 in IPEC (by metabolic labeling with $^{32}P_i$), or of passages 1 and 5 in PM cells (by hybridization with one oligonucleotide complementary to the leading RNA).

Figure 9 shows the encapsidation of defective genomes A, B and C. Figure 9A shows an agarose gel stained with ethidium bromide, in which the RNA extracted from purified virions of passage 1 and passage 41 are analyzed by means of centrifugation through a 15% sucrose cushion (w/v). In the lane of passage 41, RNAs A, B and C can be observed, as well as the parental genome. The bars on the left indicate mobility markers in kb. Figure 9B shows the results of the analysis of the RNA of passage 41 virions purified by centrifugation through sucrose cushions or continuous gradient, by Northern-blot assay with an oligonucleotide complementary to the leader RNA. Commercial GibcoBRL RNAs and RNA from passage 1 virions (lane a) were used as markers. Lanes b and c, RNA extracted from virions sedimented through 31% and 15% sucrose cushions (w/v), respectively. Lanes d and e, RNA extracted from virus purified through a continuous sucrose cushion, fractions of 1.20 and 1.15 g/ml density, respectively.

Figure 10 shows the strategy for the cloning of defective RNAs DI-B and DI-C, in which a schematic representation can be observed of the complementary DNA fragments (cDNA) obtained by RT-PCR, using as template genomic RNA of total length (A), DI-B (B) and DI-C (C). The dotted lines indicate absence of the anticipated fragment due to its large size. The defective RNAs were cloned into four overlapping fragments (a, b, c and d), represented by lines; the numbers below these lines indicate fragment size determined in agarose gels. The oligonucleotides used as primers and their polarity are indicated by means of arrows and numbers. Oligonucleotide sequence is shown in Table 2. Striped or open boxes in (A) indicate the relative position of the viral genes: pol, polymerase; S, M and N, structural genes; 3a, 3b, sM and 7, small ORFs. The shaded thin boxes indicate the leader sequence.

Figure 11 shows the results of the electrophoretic analysis of PCR products obtained in the amplification of defective RNAs. The RNA of purified virions THER-1p1 or THER-1p41 was used as a template in an RT-PCR reaction with oligonucleotides 1 and 2 (a), 3 and 4 (b), 5 and 6 (c), or 7 and 8 (d), whose sequence and position in the parental genome is indicated in Table 2. The lane corresponding to the RNA template of passage 1 (parental genomic RNA) or of passage 41 (parental RNA, DI-A, DI-B and DI-C), and the lane of DNA mobility markers (M, GibcoBRL) are indicated in each case. The numbers in bold type indicate the size in kb of the amplification products specific for defective RNAs. RNAs B+C, RNAs B and C: purified bands in an experiment where the RNAs of THER-1 STp41 virus were fractionated in gel. RNAs B and C migrate very close, and were cut as a single band.

Figure 12 shows the complete RNA DI-C cDNA sequence (see SEC. DI No. 24) obtained by the sequencing of overlapping fragments of the a, b, c and d cloning. RNA DI-C has kept four discontinuous parental genome regions: I, II, III and IV. The flanking sites of these regions are indicated with arrows. The translation of the three ORFs present in genome DI-C is indicated: chimeric ORF of 6.7 kb resulting from the fusion of discontinuous regions I and II in phase; the mini-ORF of three amino acids preceding it in phase, and the ORF which initiates in the AUG of gene S. Highly homologous regions — with the proteic domains described for other coronaviruses as those responsible for the polymerase and helicase activities, and metal ion binding sites — appear shaded. CTAAAC transcription promoter sequences appear shaded. The overlapping area between ORFs 1a and 1b (41 nucleotides) appears shaded, the slippery sequence of the ribosome appears underlined, and the ORF1a termination codon in a box. In positions 637, 6397 and 6485 the specific changes with respect to the parental genome are

indicated. The nucleotides present in the parental genome in these positions are indicated.

Figure 13 shows a diagram of the RNA DI-C structure. Total genomic length appears to the right of the boxes. RNA DI-C contains four discontinuous TGEV genome regions (I, II, III and IV). These regions comprise 2.1 kb of the 5' end of the genome, almost complete ORF1b including the overlapping area between ORFs 1a and 1b, the initiation of gene S, incomplete ORF7 and untranslated region 3'. The letters and numbers above the parental genome box indicate viral genes. The numbers below the box indicate the position of the flanking nucleotides of the discontinuous regions in the parental genome, taking as reference the sequence of the TGEV PUR46-PAR isolate. In the box corresponding to RNA DI-C, the length of the four discontinuous regions is indicated in nucleotides. In the third box it is indicated the number of nucleotides derived from each viral gene, taking into account that ORFs 1a and 1b overlap with each other 43 nucleotides in the parental genome. The ORFs predicted in the computer analysis are indicated with arrows or arrowheads. Pnt, pseudoknot; Pol, polymerase; Mib, metal ion binding; Hel, helicase; Cd, conserved domain.

Figure 14 shows the structure of the RNA DI-B. RNA DI-B contains three discontinuous regions (I, II and III) of the TGEV genome, comprising 2.1 kb of the 5' end of the genome, complete ORF1b including the overlapping area between ORFs 1a and 1b, the initiation of gene S, the termination of ORF7, and the untranslated region of 3' end. Letters and numbers over the parental genome box indicate viral genes. The numbers underneath the box indicate the position in the parental genome of the flanking nucleotides of the discontinuous regions, taking as reference the sequence of the TGEV PUR46-PAR isolate. Size heterogeneity of the deletion occurring between discontinuous regions II and III is responsible for the actual existence of a DI-B genome population. In the second and third boxes are indicated the length in nucleotides of the three discontinuous regions for the largest and smallest sized genomes, respectively. In the third box it is indicated the number of nucleotides derived from each viral gene, taking into account that ORFs 1a and 1b overlap each other for 43 nucleotides in the parental genome. The ORFs predicted by the computer analysis are indicated with arrows or arrowheads. Pnt, pseudoknot; Pol, polymerase; Mib, metal ion binding; Hel, helicase; Cd, conserved domain.

Figure 15 shows the secondary and tertiary RNA structures in the overlapping zone between ORFs 1a and 1b in the RNA DI-C. (A) Structure predicted when considering the region closest to the fork-like structure presenting complementarity to the nucleotides of the knot thus constituting the pseudoknot (nucleotides 2354 to 2358). The slippery sequence UUUAAAC is underlined. ORF1a termination codon is indicated in the box. (B) Schematic representation of this pseudoknot, which involves two sequence complementarity sections (stems: S1 and S2). The slippery sequence is represented in a box. (C) An alternative model taking into account the sequence of nucleotide 2489 to 2493 in the folding of the pseudoknot. This structure contains an additional complementarity sequence (stem) section. (D) Schematic representation of the pseudoknot, in which the three stems are marked: S1, S2 and S3.

Figure 16 shows the mapping of RNAs DI by hybridization with oligonucleotides specific to the virus in Northern-blot assays. The RNA of THER-1-STp41 virus was fractionated in agarose gels until a clear separation of the parental genome RNAs and DI A, B and C was obtained. The RNA was transferred to nylon filters which were hybridized with several oligonucleotides labeled with $^{32}\text{P}_i$, hybridized with the parental genome (+),

and hybridized (+) or not (-) with the defective genomes. The approximate localization of the sequences complementary to the oligonucleotides in the parental genome is indicated by arrows. Their exact sequence and position are indicated in Table 3. All the oligonucleotides hybridized with the parental genome and gave the expected results with RNAs B and C.

Figure 17 shows an outline of the method for the obtainment of vaccinal viruses by transfection of infected cells with RNA DI-C. A prototype outline is illustrated with the construction that enabled the production of DI-C RNA by *in vitro* transcription, maintaining the 5' and 3' ends present in the original defective particle. The sequence of the T7 promoter [PrT7] and the sequence of the autocatalytic ribozyme of the hepatitis delta virus (HDV) [Rz HDV] were cloned flanking the DI-C RNA sequence. The position of the autocatalytic cleavage introduced by the ribozyme is marked above the sequence. The arrows indicate the positions of the internal transcription promoter sequences maintained in a natural form in the RNA DI-C. L, leader. T7 ϕ , T7 bacteriophage transcription termination signals. Virions encapsidating both the helper virus as well as the defective genomes in which the heterologous genes had been cloned were recovered, when the *in vitro* transcribed RNAs were transfected into ST cells infected with the corresponding helper virus.

Figure 18 shows a prototype outline of the construction that enabled the production of pDIA-6A.C3 by *in vitro* transcription, maintaining the 3' and 5' ends present in the original defective particle. The sequence of the bacteriophage T7 promoter [PrT7] and the presence of the autocatalytic ribozyme of the hepatitis delta virus (HDV) [RzHDV] were cloned flanking the cDNA sequence coding for an autoreplicative RNA. Plasmid pDIA-6A.C3 contains the gene coding for monoclonal antibody 6A.C3 which neutralizes TGEV [see Example 4]. The cloning of the heterologous gene was done after ORF1b, following the S gene initiation codon (AUG), and in reading phase with this gene (IGS: intergenic sequence; L: leader sequence; D: diversity region; J: joining region; VH: variable module of the immunoglobulin heavy chain; CH: constant module of the immunoglobulin heavy chain; VK: variable module of the immunoglobulin light chain; CK: constant module of the immunoglobulin light chain; polyA: polyA sequence; T7 ϕ : T7 transcription terminator].

DETAILED DESCRIPTION OF THE INVENTION

This invention provides heterologous DNA expression vectors, based on recombinant defective viral genomes expressing, at least, an antigen suitable for the induction of immune response against various infectious agents of different animal species, or an antibody affording protection against an infectious agent, provided with high safety and cloning capacity, and which may be designed so that their species specificity and tropism may be easily controlled.

The term "infectious agent" in the sense in which it is used in this description includes any viral, bacterial or parasitic infectious agent that can infect an animal and cause a pathology.

The term "animal species" includes animals of any species, usually mammals, and swine, canine or feline in particular.

In a specific realization of this invention, expression vectors are obtained based on recombinant defective viral genomes expressing antigens suitable for the induction of systemic and secretory immune responses, for the prevention of mucosal infections, designed to enable an easy control of species specificity and their tropism for the infection

of enteric or respiratory mucosae, which makes them quite adequate for the induction of mucosal and lactogenic immunity, of particular interest in the protection of newborn animals against infections of the intestinal tract. In another specific realization of this invention, an expression vector is provided based on a recombinant defective viral genome expressing, at least, one antibody which affords protection against an infectious agent.

The expression vectors obtained by means of this invention comprise a defective viral genome derived from a virus, preferably, a virus with RNA genome and positive polarity, that maintains the 3' and 5' ends of the parental virus, has internal deletions and depends on a helper virus for its replication. Therefore, the invention provides, additionally, a defective virus genome comprising the genome of a parental virus having viral replicase recognition signals located at the 3' and 5' ends, comprising also internal deletions, and in which the aforesaid defective viral genome depends on a helper virus supplying the functional and structural proteins for the replication and encapsidation of the recombinant defective viral genome. In a specific realization, the defective viral genome comprises, additionally, the complete sequence coding for the parental virus replicase. In this case, if so desired, the helper virus can provide only the structural proteins required for the encapsidation of the recombinant defective viral genome or, alternatively, the functional and structural proteins for the replication and encapsidation of the recombinant defective viral genome. When the virus from which the recombinant defective genome derives is a virus with RNA genome, the expression vector comprises the cDNA complementing the aforesaid defective RNA or a cDNA substantially complementing the aforesaid defective RNA.

The vectors provided by this invention have a high cloning capacity—at least 18 kb—which is the greatest cloning capacity described for a vector based on RNA eukaryotic viruses. Additionally, these vectors have a high safety level because they (a) are based on defective genomes, (b) comprise RNA genomes and do not use DNA as a replicative intermediary, and c) are based on viruses growing in the cytoplasm of infected cells, all of which prevents the defective genome from recombining with the cell chromosome.

In a specific realization of this invention, the obtainment of defective RNA genomes derived from coronaviruses, in particular from TGEV, is described. These genomes have the additional advantage of a very low TGEV recombination frequency ($<1 \times 10^9$), which prevents the defective genome from recombining easily with the helper virus genome. However, even though this recombination might actually take place, an attenuated virus would be obtained since the invention contemplates the convenience of using the same attenuated virus both as helper virus as well as starting material for the obtainment of the defective genome.

The defective genomes constituting the basis of such vectors can be obtained in different cell systems by means of undiluted serial passages of the virus from which they derive. The DI particle generation frequency can vary much in different virus-cell systems; for this reason it is advisable to make the passages with different virus isolates in different cell lines with the aim of selecting the proper isolate and cell line. After a certain number of passages, the viruses are isolated and then used to analyze the intracellular RNAs produced in the infection with the purpose of observing the possible appearance of bands not corresponding to any viral mRNA, in which case, in order to analyze the nature of these new RNAs—subgenomic or defective—the undiluted serial passages with the parental virus are continued. After some passages, the evolution of the RNA pattern is

analyzed throughout the serial passages and, for this purpose, cells of the suitable cellular system are infected with viruses originating from different passages and the produced RNAs are analyzed by conventional techniques, for example, metabolic labeling with $^{32}\text{P}_i$ or hybridization with a suitable oligonucleotide. A detailed description of the obtainment and characterization of some defective RNAs derived from TGEV is made in Example 1.

With the defective RNAs it is possible to obtain the corresponding cDNA — complementing or substantially complementing— the aforesaid defective RNAs, by means of a reverse transcriptase (RT) reaction and polymerase chain reaction (PCR) amplification, hereinafter RT-PCR. After this, it is possible to clone the cDNA in appropriate plasmids, for example Bluescript II, under the control of efficient promoters. The resulting plasmids contain the defective viral genome under the control of some regulatory elements, containing signals for the regulation and control of replication and for the initiation and termination of transcription and translation. Therefore, these plasmids can include polyA sequences, auto-catalytic cut sequences or for the recognition of restriction enzymes allowing the insertion of the heterologous DNA, and the corresponding regulation, control and termination signals.

The plasmids thus obtained, containing the defective genome, or the corresponding cDNA, can be manipulated by conventional genetic engineering techniques in order to clone with increased efficiency, at least, one heterologous DNA sequence coding for a specific activity, under the control of the promoter of a gene present in the defective genomes or any other promoter of the virus from which the defective genome or variant of these promoters derives, and of the regulatory sequences contained in the resulting expression vector. Example 2 describes the generation of expression vectors coding for antigens inducing protection against different viruses.

The expression vectors obtained from this invention can express one or more activities, such as one or more antigens capable of inducing immune responses against different infectious agents, or one or more antibodies providing protection against one or more infectious agents. In one specific and preferred realization, these vectors express at least one antigen capable of inducing a systemic immune response or mucosal immune response against different infectious agents that propagate in respiratory or enteric mucosae. In another specific and preferred realization, the said expression vectors express, at least, one gene coding for the heavy and light chains of an antibody of any isotype (for example: IgG₁, IgA, etc.) that confers protection against an infectious agent. In a specific case the antibody expressed is the monoclonal antibody identified as 6A.C3 (see Example 4) which neutralizes TGEV, expressed with isotypes IgG₁ or IgA in which the constant part of the immunoglobulin is of porcine origin.

In a specific realization of this invention, cloning of the heterologous genes in a plasmid, containing one cDNA of a defective RNA derived from, was done after ORF1b, following the S gene initiation codon (AUG), and in reading frame with this gene (Example 2). Alternatively, the heterologous DNA sequences can be cloned in other areas of the genome, for example, in the zones corresponding to ORFs 1, 2 or 3 of TGEV. From the resulting plasmids, RNAs were expressed using a suitable polymerase, with which appropriate cells —previously infected with an attenuated helper virus— were transformed, enabling to recover virions containing the helper virus genome and other virions with defective genome (Figure 17).

Alternatively, this invention's expression vectors allow the expression of one or several genes using the strategy described above. To that end, one or several promoters

can be used, or a promoter and several internal ribosome entry sites (IRES) or, alternatively, several promoters and an internal ribosome entry site.

This invention also provides a recombinant system to express heterologous proteins comprising (a) the vector described above and (b) a helper virus which facilitates the proteins involved in the replication and encapsidation of the recombinant defective viral genome. Therefore, a recombinant system for the expression of heterologous proteins is provided, based on recombinant defective viral genomes expressing protein with at least one specific activity, comprising:

a) a recombinant vector containing a defective viral genome for which, in its case, a cDNA has been obtained, capable of being manipulated by means of conventional genetic engineering, containing the viral replicase recognition signals located at the 3' and 5' ends, comprising, additionally, internal deletions, and at least one internal DNA sequences coding for one activity, for example, an antigen capable of conferring systemic and mucosal immunity; or an antibody conferring protection against and infectious agent; and

b) a helper virus providing the functional and structural proteins for the replication and encapsidation of the defective genome.

Alternatively, the aforesaid recombinant system for the expression of heterologous proteins comprises an expression vector, of the type described above, comprising the complete sequence coding for the parental virus replicase and a helper parental virus which provides structural proteins for the encapsidation of the defective genome and, optionally, the functional proteins (replicase) for the replication of the defective viral genome.

These systems enable the expression, either of antigens capable of inducing an immune response or of antibodies that confer protection against infectious agents, for which reason they are suitable to be used with vaccinal purposes and for protection against infections.

This invention also provides vaccines capable of inducing protection against infections caused by various infectious agents in different animal species comprising (i) the recombinant system described above, consisting of: (a) an expression vector based on a defective viral genome in which the heterologous DNA sequence is cloned, and (b) the helper virus collaborating in the replication of the defective genome together with, optionally, (ii) a pharmaceutically acceptable excipient. The vaccines provided by this invention are, therefore, suitable for the conferring of immunity against various infectious agents affecting different animal species.

"To confer immunity", in the sense used in this description, should be understood to mean the starting in a receptor organism (animal to be treated), by the recombinant system as described above, of the suitable mechanisms, such as antigen-presenting cells, B and T lymphocytes, antibodies, substances potentiating cell immune response (interleukines, interferons, etc.), cell necrosis factors and similar substances that produce protection in animals against infections caused by pathogenic agents.

The vaccines provided by this invention can be monovalent or multivalent, depending on whether the expression vectors present in the recombinant system express one or more antigens capable of inducing an immune response against one or more infectious agent. The expression vectors can be monovalent or polyvalent depending on whether they express one or more antibodies conferring protection against one or more infectious agent.

Species specificity is controlled in such a way that the helper virus will express an envelope protein suitable for recognition by the cell receptors of the corresponding species. A specific group of vaccines obtained from this invention comprise as helper virus a coronavirus, preferably a porcine, canine or feline coronavirus.

These vaccines are especially indicated against infectious agents that affect the porcine, canine and feline species, infecting the mucosae or using mucosae as the route of entrance.

A specific realization of this invention provides monovalent vaccines capable of protecting pigs, dogs and cats against various porcine, canine and feline infectious agents, and tropism is controlled by expressing the S glycoprotein of a coronavirus.

The monovalent vaccines against porcine infectious agents can contain an expression vector expressing an antigen selected from the group composed essentially of antigens of the following porcine pathogens: *Actinobacillus pleuropneumoniae*, *Actinobacillus suis*, *Haemophilus parasuis*, Porcine parvovirus, *Leptospira*, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Clostridium* sp., *Serpulina hyodysenteriae*, *Mycoplasma hyopneumoniae*, porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus, rotavirus, or against the pathogens that cause porcine reproductive and respiratory syndrome, Aujeszky's disease (pseudorabies), swine influenza, transmissible gastroenteritis and the etiologic agent of atrophic rhinitis and proliferative ileitis.

The monovalent vaccines against canine infectious agents can contain an expression vector expressing an antigen selected from the group constituted essentially of antigens of the following canine pathogens: canine herpesviruses, canine adenovirus types 1 and 2, canine parvovirus types 1 and 2, canine reovirus, canine rotavirus, canine coronavirus, canine parainfluenza virus, canine influenza virus, distemper virus, rabies virus, retrovirus and canine calicivirus.

The monovalent vaccines against feline infectious agents can contain an expression vector expressing an antigen selected from the group constituted essentially of antigens of the following feline pathogens: feline calicivirus, feline immunodeficiency virus, feline herpesviruses, feline panleukopenia virus, feline reovirus, feline rotavirus, feline coronavirus, feline infectious peritonitis virus, rabies virus, feline *Chlamydia psittaci*, and feline leukemia virus.

The vectors can express an antibody that confers protection against an infectious agent, for example, a porcine, canine or feline infectious agent, such as those described above. In a specific realization, some vectors were produced expressing the recombinant monoclonal antibody identified as 6A.C3 which neutralizes VGPT.

The vaccines obtained from this invention are capable of protecting piglets by means of inducing lactogenic immunity, which is of special interest in the protection of neonatal piglets against infections of the intestinal tract.

In general, the vaccines obtained from this invention can contain a quantity of antigen capable of introducing into the animal to be immunized a helper virus a titer of, at least, 10^8 plaque forming units (pfu).

As excipient, a diluent such as physiological saline serum or other similar saline solutions may be used. Likewise, these vaccines can also contain an adjuvant like those commonly used in the formulation of vaccines: aqueous (aluminum hydroxide, QuilA, alumina gel suspensions and similar), or oily [based on mineral oils, glycerides and fatty acid by-products and their mixtures, for example, Marcol 52 (ESSO Española S.A.), Simulsol 5100 (SEPIC) and Montanide 888 (SEPIC)].

These vaccines can also contain cell response potentiator substances (CRP), i.e., T helper cell (Th₁ and Th₂) subpopulation potentiator substances, such as interleukin 1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-12, g-IFN (gamma interferon), cell necrosis factor and similar substances that might, in theory, provoke cell immunity in vaccinated animals. These CRP substances could be used in vaccine formulations with aqueous or oily adjuvants. Other types of adjuvants that modulate and immunostimulate cell response can also be used, such as MDP (muramyl dipeptide), ISCOM (immuno stimulant complex) or liposomes.

This invention provides multivalent vaccines capable of preventing and protecting animals from different infections. These multivalent vaccines can be prepared from expression vectors in which the different sequences coding for the corresponding antigens have been inserted in the same recombinant vector, or by constructing independent recombinant vectors that will be mixed afterwards for their co-inoculation together with the helper virus. Therefore, these multivalent vaccines comprise a recombinant system in which the expression vector itself contains more than one DNA sequence coding for more than one infectious agent or, alternatively, the recombinant system used in the preparation of the vaccine can contain different expression vectors, each one of which expresses at least one different antigen. The actual limitation in this type of multivalent vaccines is that the mentioned expression vectors must express antigens of infectious agents of the same animal species and that the helper virus must be the suitable one for that particular species. Analogously, multivalent vaccines can be prepared that comprise multivalent vectors using sequences coding for antibodies that confer protection against infectious agents instead of sequences coding for the antigens. These vectors can contain a recombinant system comprising either an expression vector containing more than one DNA sequence coding for more than one antibody or different expression vectors expressing, each one of them, at least, one different antibody.

A specific realization of this invention provides vaccines capable of protecting pigs, dogs and cats against various porcine, canine and feline infectious agents, respectively. To that end, the expression vectors contained in the recombinant system of the vaccine must express different antigens of the mentioned porcine, canine or feline pathogens.

The vaccines of this invention can be presented in liquid or freeze-dried form and can be prepared by suspending the recombinant systems in the excipient. If the said systems are in freeze-dried form, the excipient itself can be the diluent.

Alternatively, the vaccines attained by means of this invention can be used in combination with other conventional vaccines, either as part of them or as diluent or freeze-drying fraction to be diluted with other, either conventional or recombinant, vaccines.

The vaccines provided by this invention can be administered to the animal via oral, nasal, subcutaneous, intradermal, intraperitoneal or intramuscular routes, or by aerosol.

The invention also provides a method for the immunization of animals, especially pigs, dogs and cats, against various infectious agents simultaneously —comprising the administration via oral, nasal, subcutaneous, intradermal, intraperitoneal or intramuscular routes, or by aerosol (or their combined forms)— of a vaccine containing an immunologically efficacious quantity of a recombinant system provided by the present invention.

Additionally, the invention also provides a method for the protection of newborn animals against infectious agents that infect the said animals, consisting of the administration via oral, nasal, subcutaneous, intradermal, intraperitoneal and

intramuscular routes, or by aerosol (or their combined forms), to mothers, before or during the period of gestation, or to their progeny, of a vaccine containing an immunologically efficacious quantity of a recombinant system provided by this invention.

The invention is illustrated by means of the following examples that describe in detail the obtainment of defective viral genomes, their characterization, the construction of plasmids and their manipulation with the purpose of obtaining the expression vectors and the induction of neutralizing antibodies against different infectious agents of various species.

EXAMPLE 1

GENERATION OF DEFECTIVE PARTICLES DERIVED FROM TGEV

1.1 Undiluted serial passages of TGEV strains at high multiplicity of infection (m.o.i.)

In order to promote the generation of defective particles, or the imposition of those already existing in small proportion in the viral population, serial passages of different undiluted TGEV isolates were made in different cell systems. Because the frequency with which DI particles are generated can vary much in different virus-cell systems, the passages were done with different TGEV isolates (THER-1 and PUR46-mar 1CC12) in ST (*swine testis*, swine testicle epithelial cells) cell lines.

Strain THER-1 (transmissible gastroenteritis Helper Enteric and Respiratory coronavirus, strain 1) is a mutant attenuated by 20 passages in ST cell cultures derived from the PUR46-MAD strain [Sánchez et al., *Virology* 174, 410-417 (1990)]. Strain PUR46-mar 1CC12 is also described by Sánchez et al (supra).

Each TGEV strain was passaged undiluted 35 times in ST cells. The m.o.i. of the first passage in each one of the three cases was 100 pfu per cell. The supernatant of each passage was collected between 20 and 48 hours post infection (h.p.i.), upon observance of a clear cytopathic effect—normally when the said effect was affecting more than half of the cell monolayer—and half of the volume of this supernatant was used in the infection of the next passage. Virus titer variation with passage number is shown in Figure 4. Viral titer ranged between two logarithmic units throughout the serial passages of each virus. In the case of strain THER-1, the titer in passages 30 to 46 was lower than in the first thirty passages.

The viruses that had been passaged 35 times in ST cells were used for the analysis of intracellular RNAs produced in the infection. The RNAs, metabolically labeled with $^{32}\text{P}_i$ between hours 6 and 9 post infection, were analyzed [Maniatis et al., *Molecular cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, (1982)]. In THER-1-p35 infection (THER-1 strain virus passaged 35 times at high m.o.i.) three intense bands were observed which did not correspond to any viral mRNA. These bands were located between the genomic RNA and the S gene messenger (Figure 5). To analyze the nature of these new subgenomic RNAs, undiluted serial passages were continued with strain THER-1. After 46 passages, the evolution of the RNA pattern throughout the serial passages was analyzed. To that end, ST cells were infected with virus from various passages and the produced RNAs, metabolically labeled, were analyzed in a denaturing agarose gel (Figure 5). Whereas only genomic RNAs and subgenomic viral messengers were detected in the first passages, in passage 30 three new RNAs of 22, 10.6 and 9.7 kb (RNAs A, B and C shown in Figure 5 as DI-A, DI-B and DI-C, respectively) were

detected. These subgenomic RNAs remained in stable form throughout the following 15 passages, interfering notably with genomic RNA replication and the synthesis of the mRNAs of the helper virus (Figure 5, lanes 30 to 45). These results indicate that the three RNAs generated or amplified by the undiluted serial passages are stable and that at least one of them is interfering.

1.2 Characterization of subgenomic RNAs

1.2.1 Analysis of the ends and internal regions

To determine if subgenomic RNAs A, B and C had the standard structure of a coronavirus defective RNA, and especially, if they preserved the 5' and 3' ends of the wild genome and that its small size was due to internal deletions, several hybridization assays were carried out with probes specific for the virus. To that end, the RNA from cells infected with the THER-1-STp35 virus (THER-1 strain viruses, passaged 35 times in ST cells) was extracted and its hybridization was analyzed with specific viral probes in a Northern-blot assay (Maniatis et al., *supra*) using oligonucleotides complementary to the leader and the viral 3' end sequence. In each case, the RNA from cells infected with THER-1-p1 virus (strain THER-1 virus passaged once in ST cells) and from uninfected ST cells (NI) (lanes 1 and 2 of each filter, respectively) were used as control. The oligonucleotides used as probes are complementary to the leader RNA (positions 66-91 of the 5' end of the parental genome), to the untranslated region of the 3' end (nucleotides 28524-28543 of the 5' end of the parental genome), and to structural genes M and N (positions 97-116 and 5-24 starting from the primer AUG of each gene, respectively). The bars on the right indicate the positions of the viral mRNAs and subgenomic RNAs A, B and C.

As shown in Figure 6, the two oligonucleotides hybridized with all the parental virus mRNAs, and they also detected RNAs A, B and C, indicating that these RNAs have gone through internal deletions and maintained their ends. As an initial approach to an analysis in regard to which genomic sequences were present in these RNAs, the RNA of infected cells was hybridized with oligonucleotides complementary to the genes of structural viral proteins S, M and N. None of them hybridized with the defective RNAs, suggesting that the structural protein genes had been deleted. Thus, subgenomic RNAs A, B and C maintain the parental virus ends and have internal deletions.

1.2.2 Propagation of RNAs A, B and C

In order to verify that RNAs A, B and C are defective genomes, dependent on the parental virus for their propagation in culture, ST cells were infected with virus THER-1-STp41 (THER-1 virus strain passaged 41 times in ST cells) at different m.o.i.: 10, 0.1, 0.01 and 0.001 pfu/cell. The virus resulting from this passage, collected at 10 h.p.i., was titrated and amplified in a second passage in ST cells, which in turn was used to infect new cells from which the cytoplasmic RNA was extracted (Maniatis et al., *supra*). The RNA was analyzed in a Northern-blot assay using an oligonucleotide complementary to the leader RNA. Figure 7 shows the results obtained. The m.o.i. are indicated over each lane (10^{-3} , 10^{-2} , 10^{-1} and 10 pfu/cell). As negative control was included the RNA from an infection of ST cells with THER-1-p1 virus, which does not contain subgenomic RNAs, at m.o.i. of 10 pfu/cell (first lane). In the lane corresponding to the infection with THER-1-STp41 virus at m.o.i. of 10 pfu/cell, positive control, the genomic RNAs (mRNA 1) are labeled, and so are defective RNAs A, B and C (represented as DI-A, DI-B, DI-C) and the corresponding S gene (mRNA 2).

It is observed that when the m.o.i. of the first passage (the "bottleneck" in this experiment, as the passages that follow are amplification passages) is 0.1 pfu/cell or less, RNAs A, B and C are lost, in conditions in which the genomic RNA and the mRNA of the virus are detected in the expected proportions (Figure 7). The three defective RNAs are maintained when the m.o.i. is 10 pfu/cell. Because RNAs A, B and C are found in higher proportion than genomic RNA in the THER-1-p41 virus used in the infection, these results show that the replication or propagation of these RNAs requires that the cells be infected by defective virus and also by the helper virus. Thus, RNAs A, B and C require functions of the helper virus which are to be provided *in trans*. Therefore, RNAs A, B and C are defective genomes, depending on a helper virus for their propagation.

1.2.3 *In vitro* generation, amplification, propagation and interference of DI RNA in another cell line

In vitro generation, amplification, propagation and interference of RNA DI are specific to the cell line, and for this reason the effect that a change of cell line might have on defective RNAs was studied. To that end, the THER-1-STp46 virus (THER-1 virus passaged 46 times at a high m.o.i. in ST cells) was subjected to a new series of undiluted passages, in intestinal porcine epithelial cells (IPEC) and porcine macrophages (PM). Figure 8 shows titer variation and passage number through 10 passages in IPEC (Figure 8A) and 5 passages in PM (Figure 8B). Viral yield in both cell lines was lower than what was obtained in ST cells, and the estimate is that there was a variation ranging between 20 and 0.2 pfu/cell in the m.o.i. of each passage.

The RNA produced in ST cells infected with THER-1-STp46-IPECp1 (THER-1-STp46 virus passaged one time in IPEC cells) and THER-1-STp46-IPECp10 (THER-1-STp46 virus passaged 10 times in IPEC cells) was labeled with $^{32}\text{P}_i$ and analyzed in a denaturant agarose gel (Figure 8C).

The RNA of ST cells infected with THER-1-STp46-PMp1 virus (THER-1-STp46 virus passaged one time in PM cells) and THER-1-STp46-PMp5 (THER-1-STp46 virus passaged 5 times in PM cells) was analyzed in a Northern-blot assay with an oligonucleotide complementary to the leader RNA (Figure 8C).

The results appear on Figure 8C, which shows that the three defective RNAs remained in the first passage in both cell lines, but only RNA A persisted throughout, at least, five passages in PM, and ten passages in IPEC. In both cases the positions of the RNAs corresponding to the wild genome (1) are marked, RNAs A, B and C (DI-A, DI-B and DI-C respectively) and mRNA 2 (protein S). In the lane corresponding to the THER-1-STp46-PMp5 virus RNA, the position of genomic RNA is indicated—observed only when the exposition period of the autoradiograph was tenfold the period shown on Figure 8C.

1.3 Encapsidation of defective genomes

In order to study whether defective RNAs have the capacity to encapsidate, a partial purification was done simultaneously on viruses THER-1-STp1 (THER-1 virus passaged one time in ST cells) and THER-1-STp41 (THER-1 virus passaged 41 times in ST cells) by means of centrifugation through a 15% weight/volume (w/v) sucrose cushion. The RNA was extracted from the purified virions, and analyzed in agarose gel by means of ethidium bromide staining (Figure 9A). In passage 41 virions, RNAs A, B and C were detected with the same intensity as genomic RNA, indicating that the three defective RNAs encapsidate efficiently.

To determine if the defective genomes co-encapsidate with the complete genome, or if, on the contrary, they encapsidate independently, THER-1-STp41 virus was purified by centrifugation through sucrose cushions of varying densities, or through continuous sucrose gradients. The RNA of the purified virions in each case was analyzed in a Northern-blot assay with an oligonucleotide complementary to the leader RNA (Figure 9B). When centrifugation was done through a sucrose cushion of 31% (w/v) ($d = 1.19$ g/ml), only wild genome was detected in the sedimented virions. However, when a sucrose cushion of lower density, 15% (w/v) ($d = 1.11$ g/ml), was used, the three defective RNAs were detected, in addition to the complete genome. In a continuous sucrose cushion (15-42%, w/v) it was possible to enrich the defective virions in the upper fractions of the gradient (density close to 1.15 g/ml), and the standard virions in the lower fractions (density close to 1.20 g/ml), as shown on lanes d and e of Figure 9B. The upper band in each lane corresponds to the wild type genomes and to defective genome A (DI-A), and the lower band corresponds to defective genomes B and C (DI-B and DI-C). These results indicate that RNAs A, B and C encapsidate efficiently, and that genomes DI-B and DI-C (10.6 and 9.7 kb) do so independently from the wild type genome, in defective virions that are lighter than standard virions.

1.4 Cloning and sequencing of defective RNAs B and C. Determination of their primary structure.

1.4.1 Synthesis of complementary DNA and amplification of RNAs B and C.

The size of defective RNAs B and C had been estimated, based on their mobility in electrophoresis gels, in 10.6 and 9.7 kb, respectively. On account of their large size, it was not possible to amplify the defective RNAs in a single reverse transcriptase and polymerase chain reaction (RT-PCR) using primers complementary to genome ends. In order to overcome this limitation, the defective genomes were amplified in four independent reactions, using pairs of primers allowing four overlapping fragments to cover the total genome length in every case. These overlapping fragments were designated as *a*, *b*, *c* and *d*, arranged from the 5' end to the 3' end (Figure 10). The THER-1-STp41 virus RNA extracted from purified virions was used as a template. This RNA contained the three defective RNAs A, B and C, in addition to the parental genome. As a control, an amplification of the genomic RNA of the THER-1 wild virus was carried out simultaneously.

The sequence and position of the oligonucleotides used as primers in the RT-PCR reaction is indicated in Table 2.

Table 2
Characteristics of the oligonucleotides used as primers in the RT-PCR reactions

<u>SEC. ID. No.</u>	<u>Polarity</u>	<u>ORF Coronavirus</u>	<u>Position in the RNA DI-C^{b)}</u>	<u>Restriction Site</u>
1	+	Leader TGEV	15-41	-
2	-	ORF1a FIPV	1874-1887	-
3 ^{a)}	+	ORF1a TGEV	1524-1550	<u>XbaI</u>
4 ^{a)}	-	ORF1b TGEV	4365-4389	<u>XbaI</u>

5 ^{a)}	+	ORF1b HCV229E	4097-4114	<u>EcoRI</u>
6 ^{a)}	-	ORF1b TGEV	7633-7650	<u>EcoRI</u>
7	+	ORF1b TGEV	7633-7650	-
8 ^{a)}	-	3' UTR TGEV	9691-9707	<u>SpeI</u>
9	+	ORF1b TGEV	8251-8270	-

a). A restriction site in 5' has been included to facilitate its posterior cloning.

b). The position of the oligonucleotide in the corresponding ORF is in relation to the sequence shown on Figure 12.

The amplification by RT-PCR with primers 1 and 2, of the THER-1-STp41 virus RNA and the parental virus THER RNA gave rise to a dominant PCR product of 1.9 kb (Figure 11, fragment a). The minor bands observed in this reaction are due to unspecific hybridizations, as they appear in the two lanes. The same RT-PCR reaction was performed starting from an agarose fraction containing a pool of DI-B and DI-C RNAs extracted from a purification with gel, with the same results. This indicates that fragment a is common to all RNA DIs, and corresponds to the 1.9 kb region of the 5' end of the wild TGEV genome.

The amplification with oligonucleotides 3 and 4 gave rise to a unique PCR 2.8 kb product starting from the THER-1-STp41 virus RNA (Figure 11, fragment b). No PCR product was obtained from the THER-1 control virus RNA, as the size of the expected product was 12 kb. Based on these data, it can be deduced that at least one defective genome has one *b* fragment of 2.8 kb, and that the others have the same fragment or a larger one which is not detectable in PCR reactions due to its large size.

Oligonucleotides 5 and 6, separated by 4.6 kb in the parental genome, gave rise to two different products of 3.5 and 4.6 kb from the THER-1-STp41 virus RNA (Figure 11, fragment c). The 4.6 kb product was also obtained from the wild virus RNA used as control. These results suggest that fragment c contains one deletion in at least one defective genome (probably in DI-C, the most abundant defective genome), giving rise to a 3.5 kb fragment by PCR. The 4.6 kb fragment derives from the parental genome present in the THER-1-STp41 virus RNA population, and from those defective genomes that have maintained this region of the genome.

The amplification by RT-PCR with primers 7 and 8 of the parental virus genomic RNA did not generate any bands (Figure 11, fragment d), since the separation between these oligonucleotides is 9.5 kb in the complete genome (Figure 10). In contrast, two very intense bands of 1.9 and 2.1 kb were observed when the THER-1-STp41 virus RNA was used as template. These bands appear as a broad continuous band, corresponding to fragment d (Figure 11), probably because they co-migrate with a group of minor bands around the 1.9 kb band, preventing their resolution in gels. Heterogeneity has been observed in the size of cloning fragment d (see below).

1.4.2 Assigning amplification products (*a*, *b*, *c* and *d*) to the different defective RNAs.

In order to assign the *d* fragments of sizes varying between 1.9 and 2.1 kb to the different defective genomes, the THER-1-STp41 virus RNA, which had been used as a template, was fractioned in an agarose gel until a clear separation was achieved of the bands corresponding to the RNAs of the wild genome, DI-A, DI-B and DI-C. The bands corresponding to each one of these four RNAs were cut independently and used as a template in the amplification reaction of RT-PCR with oligonucleotides 8 and 9. Starting from the purified genomic band RNA, no PCR product was obtained. From RNA DI-B, a

predominant 1.9 kb PCR product was obtained, although less abundant DNAs were also obtained, of variable size close to 1.9 kb, which indicates a certain heterogeneity in this zone. The amplification of RNA DI-C gave rise to a dominant 2.1 kb PCR product. These results allowed to assign the 1.9 kb fragment to the defective RNA B, and the 2.1 kb fragment to RNA DI-C.

Once the *d* fragments had been assigned, the 3.5 and 4.6 kb *c* fragments obtained with primers 5 and 6 were assigned to defective RNAs C and B, respectively, since the sum of fragments *a* to *d* resulting from this assignment coincided in each case with the sizes of RNAs B and C, estimated by mobility.

Once the complete sequence of genomes B and C had been determined, fragment assignment was verified by amplifying each purified band RNA, using oligonucleotides flanking specific deletions. The assignment of the fragments was also confirmed by Northern-blot assay, using oligonucleotides mapping the DI-B regions that were not present in DI-C, and vice versa.

1.4.3 Cloning and sequencing the overlapping fragments *a*, *b*, *c*, and *d*.

The four overlapping DNA fragments *a* (1.9 kb), *b* (2.8 kb), *c* (3.5 kb) and *d* (2.1 kb), complementary to RNA C, were cloned in Bluescript SK⁺. At least two clones derived from independent RT-PCR reactions were sequenced. The sequence of the positions that did not coincide in the different clones (possibly errors of the Taq polymerase) were sequenced directly from the corresponding uncloned PCR products. Following this procedure, the RNA DI-C consensus sequence was determined. An average of 1 error of Taq polymerase was obtained each copied 1.2 kb. The complete sequence of the DI-C genome is shown on Figure 12.

The complete RNA DI-C sequence obtained this way was compared with the ORFs 1a and 1b sequence of the PUR46-PAR virus [Eleouet et al., Virology 206, 817-822 (1995)], and with the sequence determined in our laboratory for the other THER-1 virus ORFs. In the complete RNA DI-C sequence, 14 nucleotide differences were found in comparison with the sequence of strain PUR46-PAR. These positions were sequenced in strain THER-1, the parental virus of the defective genome, in order to define the specific changes of the genomic defective RNA DI-C. The DI-C RNA sequence only presented three nucleotide differences in comparison with the corresponding sequence of the parental virus, and one insertion in position 9189, which does not affect any ORF (Figure 12).

1.4.4 Primary DI-C and DI-B genome structures.

The sequence data indicated that the DI-C genome was composed of four discontinuous parental genome regions (Figure 13) comprising: a) the 2144 nucleotides of the 5' end of the genome; b) 4540 nucleotides corresponding to the region between positions 12195 and 16734 of the parental genome, which includes the overlapping area between ORFs 1a and 1b, and approximately the 5' half of ORF 1b; c) a region of 2531 nucleotides corresponding to positions 17843-20372 of the wild genome, and which comprises the 3' half of ORF1b and the first 8 gene S nucleotides; and d) the 493 nucleotides of the 3' end.

The primary structure of the DI-B genome was determined by sequencing of cloned fragments *a* and *b* (common to genome DI-C), *c* (like the parental genome) and *d* (specific to genome DI-B). Genome DI-B is composed of three discontinuous regions of the genome (Figure 14): a) the 2144 nucleotides of the 5' end of the genome, common to

all DI-B clones, and identical to region I of RNA DI-C; b) a region variable in size, of 8178-8243 nucleotides corresponding to positions 12195-20369 to 20436 of the parental genome, and which includes the overlapping zone between the two ORFs of gene 1, the complete ORF1b, and the first nucleotides of gene S; and c) nucleotides 278 to 303 of the 3' region of the genome.

The clones constituting the population designated as genomes DI-B differ in the size of the deletion that took place between regions II and III, which starts at the beginning of gene S (between nucleotides 6 and 73) and finishing at the end of gene 7 (between nucleotides 195 and 233).

The 5' end sequence of parental RNA THER-1 was determined by direct sequencing of the RNA, and is 5'-NCUUUUAAG-3'. The nature of the first "N" nucleotide of the sequence has not been determined. So far, the sequence of the 5' end of three TGEV isolates, PUR46-PAR, PUR46-BRI and FS772/70, has been described [Eleouet et al., *supra*; Page et al., *Virus Genes* **4**, 289-301 (1990); Sethna et al., *J. Virol.* **65**, 320-325 (1991)] and they all differ in the first nucleotide. The sequence of the defective RNAs leader must be the same as that of the parental virus leader, in view of the interchange of leaders that takes place in a coronavirus infection [Makino et al., *J. Virol.* **57**, 729-737 (1986)].

The three defective RNAs contain polyA, as they join themselves to oligo dT columns (results not shown).

1.4.5 RNAs B and C keep the overlapping region between ORFs 1a and 1b, which includes the motive responsible for the translocation (-1) of the ribosome

In accordance with the sequences assigned to genomes DI-C and DI-B, it is possible to predict ORFs of 6370 and 10003 nucleotides, respectively, starting at nucleotide 315, counting from the 5' end of the genome. The RNA DI-C ORF ends at the termination codon generated at the joint site of discontinuous regions II and III, where the internal deletion had taken place in ORF 1b, at position 6685 of the DI-C genome. The DI-B genome ORF ends at the natural termination codon of ORF1b.

The two defective RNAs keep the overlapping zone between ORFs 1a and 1b, which includes the sliding sequence and the tertiary structure motive *pseudoknot*, responsible for the translocation (-1) of the ribosome in this zone (Eleouet et al., *supra*). Figure 15 shows the possible RNA secondary and tertiary structures in this zone. The structure proposed by Eleouet et al. for the *pseudoknot* in this zone, is the one indicated in C and D; however, there are other possible structures (as indicated in A and B), although it is not known which is the correct one.

A description has been made, indicating that the translocation occurs with an efficiency of 20% in TGEV (Eleouet et al., *supra*) and enables the continuous translation of gene 1. The fact that RNAs DI-B and DI-C (and probably DI-A RNA) keep this region of the parental genome suggests that it could be necessary for RNA replication or for genome propagation.

There are two other small ORFs in defective genomes DI-C and DI-B. One of them, previous to the long reading frame, codes for a peptide of three amino acids, which is also found in the wild type genome, whose function is unknown. The other ORF starts in both cases in the AUG of gene S, and codes for a peptide of 16 amino acids in DI-C, and a peptide of variable size in DI-B. It is unknown whether these ORFs are functional. The only two transcription promoter consensus sequences (CUAAAC) of the virus that

are kept are precisely those preceding gene 1 and gene S, in defective RNAs B and C. These sequences are marked in Figure 12.

Figure 16 shows the mapping of RNAs A, B and C by hybridization with oligonucleotides specific to the virus in Northern-blot assays. The THER-1-STp41 virus RNA was fractionated in agarose gels until a clear separation of the RNAs from the parental genome and DI, A, B and C had been obtained. The RNA was transferred to nylon filters which hybridized with various oligonucleotides marked with $^{32}\text{P}_i$, hybridized with the parental genome (+), and hybridized (+) or not (-) with the defective genomes. The approximate locations of the sequences complementary to the oligonucleotides in the parental genome are shown marked with arrows. Their exact sequence and position appear in Table 3. All the oligonucleotides hybridized with the parental genome, and the expected results with RNAs B and C were obtained.

Table 3

<u>ON</u>	<u>ID Sec. No.</u>	<u>Polarity</u>	<u>Gene in TGEV</u>	<u>Position in the genome^{a)}</u>
1	10	-	Leader	66-91
2	11	-	ORF1a	2151-2170
3	12	-	ORF1a	6121-6140
4	13	-	ORF1a	8684-8703
5	14	-	ORF1a	12261-12280
6	15	-	ORF1b	14148-14167
7	16	-	ORF1b	17363-17381
8	17	-	ORF1b	18792-18811
9	18	-	gene S	1055-1074
10	19	-	gene S	1980-1999
11	20	-	gene S	3600-3619
12	21	-	gene M	97-116
13	22	-	gene N	5-24
14	23	-	UTR-3'	28524-28543

a): The position in the genome is indicated as the number of bases starting from the 5' end of the wild type virus genome for oligonucleotides (ON) complementary to gene 1 (ORF1a and ORF1b) and the untranslated region of 3' end (3'-UTR); and from the first nucleotide of the primer ATG of the corresponding gene to nucleotide 5' of the ON in the case of primers mapping in genes S, M and N.

EXAMPLE 2

GENERATION OF EXPRESSION VECTORS

The cDNA coding for RNA DI-C has been cloned in a Bluescript II plasmid, under the control of the phage T7 promoter. This cDNA includes polyA sequences, a hepatitis delta virus (HDV) ribozyme, and phage T7 termination signals. One of these plasmids, whose construction appears in Figure 17, has been denominated pDIC-1. These plasmids can be manipulated to clone in them heterologous genes under the control of the gene S promoter present in the defective genome, or another TGEV promoter, or a variant of them with increased efficiency.

The cloning of these heterologous genes was done after ORF1b, following the S gene initiation codon (AUG), and in reading phase with this gene.

From these cDNAs, RNAs were expressed using the phage T7 polymerase, with which ST cells that had been infected previously with the attenuated helper virus THER-1 were transformed, enabling to recover virions, containing the helper virus genome, and other virions, containing the corresponding defective genome. These viruses, freeze-dried in presence of 2% fetal calf serum, were used as vaccine for the induction of specific antibodies against agents that infect the gastrointestinal and respiratory tracts of pigs, dogs and rabbits.

The tropism of the vectors was specifically targeted to the porcine, canine, or feline species, using the appropriate attenuated helper viruses.

EXAMPLE 3

INDUCTION OF NEUTRALIZING ANTIBODIES

3.1 Induction of protection against porcine epidemic diarrhea coronavirus (PEDV)

Pigs were immunized using a recombinant system consisting of helper virus (THER-1), and the pDIC-1 plasmid in which the PEDV glycoprotein S gene had been cloned.

The immunizations were done by administering 10^9 pfu per piglet, via oral route.

Presence of neutralizing antibodies was assayed in the sera of animals vaccinated at 15, 30, 45 and 60 days post immunization; and presence of antibodies specific to PEDV was determined using a radio immuno-assay (RIA) (Maniatis et al., *supra*).

With the sera collected on the 45th day post immunization, total protection was provided against infection by PEDV (strain SEG86-1) in 10-day-old piglets, when these sera had been pre-incubated with the virulent virus before oral administration.

3.2 Induction of protection against canine coronavirus

Dogs were immunized using a recombinant system consisting of helper virus (canine coronavirus strain Fort Dodge), and the pDIC-1 plasmid in which the canine coronavirus glycoprotein S gene had been cloned (strain Fort Dodge).

The immunizations were done by administering 10^9 pfu per dog via oral route.

Presence of neutralizing antibodies in the sera of the animals vaccinated at 15, 30, 45 and 60 days post immunization was assayed, and presence of antibodies specific to canine coronavirus was determined using RIA.

With the sera collected on the 45th day post immunization, total protection was conferred against infection by canine coronavirus (strain Fort Dodge) in 10-day old puppies, when these sera were pre-incubated with the virulent virus before oral administration.

3.3 Induction of protection against infections caused by the arterivirus PRRSV

Pigs were immunized using a recombinant system consisting of helper virus (THER-1), and pDIC-1 plasmid in which the arterivirus PRRSV ORF3 and ORF5 (strain Fort Dodge) had been cloned.

The immunizations were done by administering 10^9 pfu per piglet, via oral route.

Presence of neutralizing antibodies was analyzed in the sera of the animals vaccinated at 15, 30, 45 and 60 days post immunization, and presence of antibodies specific to PRRSV was determined by RIA.

With the sera collected on the 45th day post immunization, total protection was provided against infection by PRRSV (strain Fort Dodge) in 10-day-old piglets, when these sera had been pre-incubated with the virulent virus before the administration via oral route.

EXAMPLE 4

GENERATION OF EXPRESSION VECTORS

Following a procedure similar to the one described in Example 2, a cDNA coding for an selfreplicative RNA has been cloned in a Bluescript II plasmid, under the control of the phage T7 promoter. This cDNA includes polyA sequences, a ribozyme of hepatitis delta virus (HDV) and the phage T7 termination signals. One of these plasmids, whose construction is shown in Figure 18 has been denominated pDIA-6A.C3. This plasmid contains the gene coding for monoclonal antibody 6A.C3 which neutralizes TGEV. The characteristics of monoclonal antibody 6A.C3 and its construction are described in Dr. Joaquín Castilla Carrión's Doctoral Thesis, entitled "*Construcción de animales transgénicos secretores de anticuerpos neutralizantes para coronavirus*", Universidad Autónoma, Madrid, Faculty of Science, December 1996, pages 43-52, 65-79.

The cloning of the heterologous gene was done after ORF 1b, following the gene S initiation codon (AUG), and in reading frame with this gene.

Starting from this cDNA, RNAs were expressed using phage T7 polymerase, with which were transformed ST cells previously infected with the attenuated helper virus THER-1, resulting in the recovery of virions containing the helper virus genome and other virions with the corresponding defective genome. These viruses, freeze-dried in the presence of 2% fetal calf serum can be used as vectors for the expression of the recombinant 6A.C3 monoclonal antibody. The tropism of the vectors was made specifically for the porcine species using the appropriate attenuated helper virus.

5

EXAMPLE 5

EXPRESSION OF NEUTRALIZING ANTIBODIES

10

Pigs were immunized using a recombinant system constituted of helper virus (THER-1), and the pDIA-6A.C3 plasmid (Example 4) containing the sequence coding for recombinant monoclonal antibody 6A.C3 which neutralizes TGEV.

15

The immunizations were done by administering 10^9 pfu per piglet via oral route. Presence of neutralizing 6A.C3 antibodies was assayed in the serum of animals vaccinated at 15, 30, 45 and 60 days post immunization using an RIA [Maniatis et al, *supra*]. The recombinant antibodies had RIA titers higher than 10^3 and are able to reduce the titer of the infectious virus more than 10^4 fold.

20

DEPOSIT OF MICROORGANISMS

25

The plasmid denominated pDIC-1, introduced in a DH-5 bacterium derived from *E. coli*, [DH5/pDIC-1], was deposited on 6th March 1996 at the European Collection of Animal Cell Cultures (ECACC), Porton Down, Salisbury, Wiltshire SP4 OJG, United Kingdom, with corresponding accession number P96030641.

Additionally, the attenuated helper virus denominated THER-1 was deposited at ECACC on 6th March 1996, with corresponding accession number V96030642.

LIST OF SEQUENCES

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: CYANAMID IBERICA, S.A.

(B) ADDRESS: CRISTOBAL BORDIU, 35

(C) CITY: MADRID

(E COUNTRY: SPAIN

(F) POSTAL CODE: 28003

(G TELEPHONE: 34 1 663 91 21

(H) TELEFAX: 34 1 663 94 01

(ii) TITLE OF THE INVENTION:

VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND
THEIR USE IN THE FORMULATION OF VACCINES

(iii) NUMBER OF SEQUENCES: 24

(iv) FORM READABLE BY COMPUTER:

(A) MEDIUM: Diskette

(B) COMPUTER: IBM PC-compatible

(C) OPERATIVE SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION ON IDENTIFIED SEQUENCE No. [ID. SEQ. No.]: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 1:

GTGAGTGTAG CGTGGCTATA TCTCTTC

27

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 2:

CCGTTGTGGT GTCACATTAA C

21

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 3:

GCCTCTAGAG GAGCTTTGTG GTTCACTTAC AC

32

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 4:

GCTCTAGAGC GTTTGAATCA ACCCCCAAAA GC

32

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 5:

GGAATTCGG GACTATCCTA AGTGTG

26

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 6:

GGAATTCCAG CAATACTATT ATCAA

25

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 7:

TTGATAATAG TATTGCTGGC

20

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 8:

GGACTAGTAT CACTATCAAA AGG

23

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 9:

GATGGATGTT GTGGTGTGAG

20

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 10:

CGAGTTGGTG TCCGAAGACA AAATCT

26

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 11:

ATACGAGCAT CAATATCACC

20

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 12:

AGAGTTGCCA CAGACTGCAG

20

(2) INFORMATION ON IDENTIFIED SEQUENCE No.: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 13:

CAGCAGTTC AAAGTTACCC

20

(2) INFORMATION ON IDENTIFIED SEQUENCE No. 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 14:

CCATTGTTAA GCCAACAACC

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 15 :

ATCACACTTA GGATAGTCCC

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 16 :

GTCTAACAAAT GTGCCAAGG

19

2) INFORMATION ON IDENTIFIED SEQUENCE No. 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 17:

GCCAGCAATA CTATTATCAA

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 18:

CACTGTGGCA CCCTTACCTG

20

5

2) INFORMATION ON IDENTIFIED SEQUENCE No. 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 19:

GTACACCCAC TATGTTGTCT

20

10

15

20

25

2) INFORMATION ON IDENTIFIED SEQUENCE No. 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

30

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 20 :

TTGCGAGTGA AAACAAATGT

20

5

2) INFORMATION ON IDENTIFIED SEQUENCE No. 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

10

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 21:

CTCACAAATCA GACGCTGTAC

20

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 22:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

30

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 22:

GACACGTTGT CCCTGGTTGG

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: monocatenary

(D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 23:

ACATTTTAAA CAATCACTAG

20

2) INFORMATION ON IDENTIFIED SEQUENCE No. 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9714 base pairs

(B) TYPE: nucleic acid

(C) NO. OF CHAINS: bicatenary

(D) TOPOLOGY: circular

(ii) TYPE OF MOLECULE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Virus of transmissible gastroenteritis of pigs (TGEV)

(B) STRAIN: THER-1

(C) INDIVIDUAL ISOLATE: DI-C

(xi) DESCRIPTION OF THE SEQUENCE: ID. SEQ. No.: 24:

NCITTTAAAG TAAAGTGAGT GTAGCGTGGC TATATCTCTT CTTTACTTT AACTAGCCTT 60
 GTGCTAGATT TTGCTTCGG ACACCAACTC GAACTAAACG AAATATTTGT CTTTCTATGA 120
 AATCATAGAG GACAAGCGTT GATTATTTCC ATTCAGTTTG GCAATCACTC CTTGGAACGG 180
 GGTGACCGA ACGGTGCAGT AGGGTTCCGT CCTATTTTCG TAAGTCGCCT AGTAGTAGCG 240
 AGTGCGGTTT CGCCCGTACA ACGTTGGGTA GACCGGGTTC CGTCCTGTGA TCTCCCTCGC 300
 CGGCCGCCAG GAGAATGAGT TCCAAACAAT TCAAGATCCT TGTTAATGAG GACTATCAAG 360
 TCAACGTGCC TAGTCTTCTT ATTCGTGACG TGTACAGGA AATTAAGTAC TGCTACCGTA 420
 ATGGATTTGA GGGCTATGTT TTGCTACCAG AATACTGTG TGACCTAGTT GATTGCGATC 480
 GTAAGGATCA CTACGTCATT GGTGTTCTTG GTAACGGAGT AAGTGATCTT AAACCTGTTT 540
 TTCTTACCGA ACCCTCCGTC ATGTTGCAAG GCTTTATTGT TAGAGCTAAC TGCAATGGCG 600
 TTCTTGAGGA CTTTGACCTT AAAATTGCTC GCACTGTCAG AGGTGCCATA TATGTTGATC 660
 AATACATGTG TGGTCTGAT GGAALACCAG TCATTGAAGG CGATTTTAAAG GACTACTTCG 720
 GTGATGAAGA CATCATTGAA TTTGAAGGAG AGGAGTACCA TTGCGCTTGG ACAACTGTGC 780
 GCGATGAGAA ACCGCTGAAT CAGCAAACTC TCTTTACCAT TCAGGAAATC CAATACAATC 840
 TGGACATTCC TCATAAATTG CCAAACTGTG CTAAGTACCA TGTAGCAACA CCACTCAAAA 900
 AGAACTCTAA AATAGTCTCG TCTGAAGATT ACAAGAAGCT TTATGATATC TTCGGATCAC 960
 CCTTTATGGG AAATGGTGAC TGTCTTAGCA AATGCTTTGA CACTCTTCAT TTTATCGCTG 1020
 CTAAGCTTAG ATGCCCGTGT GGTCTGAAA GTAGCGCGGT TGGAGATGG ACTGTTTAA 1080
 AGACTGCTG TTGTTGCTT TCTGGCAAAG TTAAGGGTGT CACTTTGGGT GATATTAAAGC 1140
 CTGGTGATGC TGTGTCACT AGTAGAGCG CAGGTAAGGG AGTTAAGTTC TTGGCCAATT 1200
 GTGTTCTTCA ATATGCTGGT GATGTTGAAG GTGTCTCCAT CTGGAAGTT ATTAATACTT 1260
 TTACAGTTGA TGAGACTGTA TGCAACCCCTG GTTTTGAAGG CGAATTGAAC GACTTCATCA 1320
 AACCTGAGAG CAAATCACTA GTTGCAATGCA GCGTTAAAG AGCATTCAAT ACTGGTGATA 1380
 TTGATGATGC TGTACATGAT TGTATCATTA CAGGAAAATT GGATCTTAGT ACCAACCTTT 1440
 TTGGTAATGT TGGTCTATTA TTCAAGAAGA CTCCATGGTT TGTACAAAAG TGTGGTGAC 1500
 TTTTGTAGA CGCTTGGAAA GTAGTAGAGG AGCTTTGTGG TTCACTCACA CTTACATACA 1560
 AGCAAAATTA TGAAGTTGTA GCATCACTTT GCACCTCTGC TTTTACGATT GTAAACTACA 1620
 AGCCAACATT TGTGGTTCCA GACAATCGTG TTAAGATCT TGTAGACAAG TGTGTGAAAG 1680
 TTCTTGTAAG AGCATTGAT GTTTTACGC AGATTATCAC AATAGCTGGT ATTGAGGCCA 1740
 AATGCTTTGT GCTTGGTCTT AAATACCTGT TGTCAATAA TGCACTTGTC AAACCTGTCA 1800
 GTGTTAAAT CCTTGGCAAG AAGCAAAAG GTCTTGAATG TGCAATCTTT GCTACTAGCT 1860
 TGGTGGTGC AACTGTTAAT GTGACACCTA AAAGAACAGA GACTGCCACT ATCAGCTTGA 1920
 ACAAGGTGA TGATGTTGTA GCACCAGGAG AGGGTTATAT CGTCATTGTT GGTGATATGG 1980
 CTTTCTACAA GAGTGGTGA TATTATTTCA TGATGTCTAG TCCTAATTTT GTTCTTACTA 2040
 ACAATGTTTT TAAAGCAGTT AAAGTTCCAT CTTATGACAT CGTTTATGAT GTTGATAATG 2100

0045003 00493

ATACCAAAAG CAAAATGATT GCAAAACTTG GTTCATCATT TGAACAAATA CCACTGGCA 2160
 CACAAGATCC AATTCGGTTC TGTATTGAAA ATGAAGTTTG TGTTGTCTGT GGTGTTGGC 2220
 TTAACATGG TTGCATGTGC GATCGTACTT CTATGCAGAG TTTTACTGTT GATCAAAAGT 2280
 ATTTAAACGA GTGCGGGGTT CTAGTGCAGC TCGACTAGAA CCCTGCAATG GTACTGATCC 2340
 AGACCATGTT AGTAGAGCTT TTGACATCTA CAACAAAGAT GTTGGCTGTA TTGGTAAATT 2400
 CCTTAAGAGC AATTTGTTCAA GATTTAGGAA TTTGGACAAA CATGATGCCT ACTACATTGT 2460
 CAAACGTGT ACAAGACCG TTATGGACCA TGAGCAAGTC TGTATAACG ATCTTAAAGA 2520
 TTCTGCTGCT GTTCTGAGC ATGACTTCTT CACATATAAA GAGGCTAGAT GTGAGTTCGG 2580
 TAATGTTCCA CGTAGGAATC TTACAAAGTA CACAATGATG GATCTTTGTT ACGCTATCAG 2640
 AATTTTGTAT GAAAAGAACT GTGAAGTTCT CAAAGAAATA CTCGTGACAG TAGGTGCTTG 2700
 CACTGAAGAA TTCTTTGAAA ATAAAGATTG GTTGTATCCA GTTGAATAATG AAGCCATACA 2760
 TGAAGTTTAT GCAAAACTTG GACCCATGTT AGCCATGCT ATGCTTAAAT GTGTTGCTTT 2820
 TTGCGATCG ATAGTGGAAA AAGGCTATAT AGGTGTTATA ACACTTGACA ACCAAGATCT 2880
 TTAATGGCAAT TTCTACGATT TCGGCGATTT CGTGAAGACT GCTCCGGGT TTGGTTGGC 2940
 TTGTGTTACA TCATATTATT CTTATATGAT GCGTTTAAAT GGGATGACTT CATGCTTACA 3000
 GTCTGAAAC TTGTGAAA GTGACATCTA TGCTTCTGAT TATAAGCAGT ATGATTTACT 3060
 AGCTTATGAT TTAACGAAC ATAAGGAGTA CCTTTTCCAA AAATACTTAA AGTACTGGA 3120
 TCGCACATAT CACCCAAAT GTTCTGATTG TACTAGTGAG GAGTGATTA TTCAATTGTC 3180
 TAAATTTAAC ACATTGTTT CTATGCAAT ACCATGACA GCTTTGGAC CACTGTCCG 3240
 TAAAGTTCAAT ATTGATGGT TACCAGTAGT TGTACTGCA GGTAACTT TCAACAACT 3300
 TGGTATAGTA TGGATCTTG ATGTAATTT AGACACATG AAGTTAGCA TGACTGATCT 3360
 TCTTAGATTT GTCACAGATC CAACACTTCT TGTAGCATCA AGCCCTGCAC TTTTAGACCA 3420
 GCGTACTGTC TGTTTCTCCA TTGCAGCTTT GAGTACTGGT ATTACATATC AGACAGTAAA 3480
 ACCAGGTCAC TTTAACAAGG ATTTCTACGA TTTCATAACA GAGCGTGGAT TCTTTGAAGA 3540
 GGGATCTGAG TTAACATTA AATTTTTT CTTTGCACAG GGTGGTGAAG CTGCTATGAC 3600
 AGACTTCAAT TATTATCGCT ACAATAGAGT CACAGTACTT GATATTGCC AAGCTCAAT 3660
 TGTTTACAAA ATAGTTGGCA AGTATTTTGA ATGTTATGAC GGTGGGTGCA TTAATGCTCG 3720
 TGAAGTTGTT GTTACAACT ATGACAAGAG TGCTGGCTAT CCTTTGAACA AATTTGGTAA 3780
 AGCTAGACTT TACTACGAAA CTCCTTCATA TGAAGAGCAG GATGCACTTT TTGCTTTAAC 3840
 AAAGAGAAAT GTTTTACCA CAATGACTCA AATGAATTTG AAATACGCTA TTTCTGGTAA 3900
 GGCAAGAGCT CGTACAGTAG GAGGAGTTT ACTTCTTCT ACCATGACTA CGAGACAATA 3960
 TCATCAGAAG CATTGGAAGT CAATTGCTGC AACACGCAAT GCTACTGTGG TCATTGGTTC 4020
 AACCAAGTTT TATGGTGGTT GGGACATAT GCTTAAAAAT TTAATGCGTG ATGTTGATAA 4080
 TGGTTGTTT ATGGGATGGG ACTATCCTAA GTGTGACCGT GCTTTACCTA ATATGATTAG 4140
 AATGGCTTCT GCCATGATAT TAGGTTCTAA GCATGTTGGT TGTGTACAC ATAATGATAG 4200

TTCTACCGC CTCTCCAATG AGTTAGCTCA AGTACTCACA GAAGTTGTGC ATTGCACAGG 4260
 TGGTTTTAT TTTAAACCTG GTGGTACAAC TAGCGGTGAT GGTACTACAG CATATGCTTA 4320
 CTCTGCTTTT ACATCTTTC AAGCTGTTTC TGCTAATGTT AATAAGCTTT TGGGGGTTGA 4380
 TTCAAACGCT TGTACAACG TTACAGTAAA ATCCATACAA CGTAAAAATT ACGATAATTG 4440
 TTATCGTAGT AGCAGCATTG ATGAAGAATT TGTGTTGAG TACTTTAGTT ATTTGAGAAA 4500
 ACACTTTTCT ATGATGATTI TATCTGATGA TGGAGTTGTG TGCTACAACA AAGATTATGC 4560
 GGATTIAGGT TATGTAGCTG ACATTAATGC TTTTAAAGCA ACACTTTATT ACCAGAATAA 4620
 CGTCTTTATG TCCACTTCTA AGTGTGGGT AGAACCAGAT CTTAGTGTG GACCACATGA 4680
 ATTTGTITCA CAGCATACAT TGCAGATTGT TGGGCTGAT GGAGACTACT ATCTTCCCTA 4740
 TCCAGACCGC TCCAGAATTT TGTCACTGG TGTGTTTGTI GATGACATAG TTAACACAGA 4800
 CATGTTIATT ATGTTAGAAC GTTACGTGTC ATTGGCTATT GACGCATACC CGCTCACAAA 4860
 ACACCTTAAG COTGCTTATC AAAAAGTGTI TTCACTCTA CTAGATTGGG TTAACATCT 4920
 ACAGAAAAAT TTGAATGCAG GTGTTCTTGA TTGTTTTCA GTGACAATGT TAGAGGAAGG 4980
 TCAAGATAAG TTCTGGAGTG AAGAGTTTTA CGCTAGCCTC TATGAAAAGT CCACTGTCTT 5040
 GCAAGCTCCA GGCATGTGTG TAGTATGTGG TTGCAAACT GTACTTCGTT GTGGAGACTG 5100
 TCTTAGGAGA CCACTTTTAT GCACGAAATG TGCTTACGAC CATGTTATGG GAACAAAGCA 5160
 TAAATTCATT ATGCTATCA CACCATATGT GTGTAGTTTT AATGGTTGTA ATGTCAATGA 5220
 TGTACAAAG TTGTTTTAG GTGCTCTTAG TTATTATTGT ATGAACCACA AACCACAGTT 5280
 GTCATTCCCA CTCTGTGCTA ATGCCAACGT TTTTGGTCTA TATAAAAGTA GTGCAGTCGG 5340
 CTCAGAGGCT GTTGAAGATT TCAACAACT TGCAGTTCT GACTGGACTA ATGTAGAAGA 5400
 TTAACAACTT GCTAACATG TCAAGGAATC TCTGAAAATT TTGCTGCTG AACTGTGAA 5460
 AGCTAAGGAG GAGTCTGTTA AATCTGAATA TGCTTATGCT GTATTAAAGG AGGTTATCGG 5520
 CCCTAAGGAA ATGTACTCC AATGGGAAGC TTCTAAGACT AAGCCTCCAC TTAACAGAAA 5580
 TTCAGTTTC ACGTGTTC AGATAAGTAA GGATACTAAA ATCAATTAG GTGAATTTGT 5640
 GTTGAGCAA TCTGAGTACG GTAGTGATTC TGTTTATTAC AAGAGCACGA GACTTACAA 5700
 ATTGACACCA GGTATGATTI TTGTGTTGAC TTCTCATAAT GTGAGTCCTC TTAAGCTCC 5760
 AATTTTAGTC AACCAAGAAA AGTACAATAC CATATCTAAG CTCTATCCTG TCTTTAATAT 5820
 AGCGGAGGCC TATAATACAC TGGTCTCTTA CTACCAATG ATAGGTAAGC AAAAATTTAC 5880
 AACTATCCAA GGTCTCTCTG GTAGCGGTAA ATCTCATTGT GTTATAGGTT TGGGTTTGT 5940
 TTACCTCAG GCGAGAATAG TCTACACTGC ATGTTCTCAT GCGGCTGTAG ACGCTTTATG 6000
 TGAACAAAGCA GCAAAACT TCAATGTTGA TAGATGTTCA AGGATAATAC CTCAAAGAAT 6060
 CAGAGTTGAT TGTTACACAG GCTTTAAGCC TAATAACACC AATGCCAGT ACTTGTTTTG 6120
 TACTGTTAAT GCTCTACCAG AAGCAAGTTG TGACATTGTT GTAGTTGATG AGGTCTCTAT 6180
 GTGTAATAAT TATGATCTTA GTGTCATAAA TAGCCGACTG AGTTACAAAC ATATTGTTTA 6240
 TGTGGAGAC CCACAGCAGC TACCAGCTCC TAGAACTTG ATTAATAAGG GTGTACTTCA 6300

0055560 "E055560"

ACCGACGAT TACCATGTTG TAACCAAAAG AATGTGCACA CTAGGACCTG ATGTCTTTT 6360
 GCATTAAGT TACAGGTGCC CAGCTGAAT TGTAAACA GTCTCTGCAC TTGTTTATGA 6420
 AATTAATTT GTCCCTGTCA ACCCAGAAFC AAGCAGTGC TTCAAAATGT TTGTAAGG 6480
 TCAGTTTGG ATTGAGTCTA ACTCTTCTAT AAACAACAAG CAACTAGAGG TTGTCAAGGC 6540
 CTTTTTAGCA CATAATCCAA AATGGCGTAA AGCTGTTTTC ATCTCACCT ATAATAGTCA 6600
 AATTAATGT GCTGGGCTC TTCTGGTTT GCAACGCAA ACTGTGGATT CCGCTCAGG 6660
 TAGTGAGTAT GATTACGTCA TCTAGCTGCT CTGAAGATT TTAATCCTGC TGCAATTCAC 6720
 GATGTGGTA ATCCAAAGG CATCCGTTGT GCTACAACAC CAATACCATG GTTTTGTAT 6780
 GATCGTATC CTATTAATAA CAATGTTAGA TGTCTGGATT ATGACTATAT GGTACATGGT 6840
 CAATGATG GTCTTATGT ATTTTGAAC TGTAATGTAG ACATGTACCC AGAGTTTTC 6900
 ATTGTTTGA GATTGATAC TCGACTCGC TCTAAATGT CTTAGAAGG TTGTAATGGT 6960
 GGTGCATTGT ATGTAATAA CCATGCTTC CACACACCAG CTTATGATAG AAGAGCTTT 7020
 GCTAAGCTTA AACCTATGCC ATTCTTTTAC TATGATGATA GTAATTGTGA ACTTGTGAT 7080
 GGGCAACCTA ATTATGTACC ACTTAAGTCA AATGTTTGA TAACAAATG CAACATTGGT 7140
 GGTGCTGCT GCAAGAAGCA TGCTGCTCT TACAGAGCGT ATGTTGAGGA TTACAACAT 7200
 TTTATGCAG CTGGTTTAC AATATGGTGT CCTCAAACT TTGACACCTA TATGCTTTG 7260
 CATGGTTTG TTAATAGCAA AGCACTTCAG AGTCTAGAAA ATGTGGCTTT TAATGTCGT 7320
 AAGAAAGGT CCTTCACCG TTTAAAGGT GACTTACCA CTGCTGTTAT TGCTGACAA 7380
 ATAATGGTA GAGATGGACC TACTGACAA TGTATTTTA CAAATAAGAC TAGTTTACCT 7440
 ACAATGTAG CTTTGAGTT ATATGCAAAA CGCAAACTG GACTCACACC TCCATTAA 7500
 ATACTTAGA ATTTAGGTGT TGTGCAACA TATAAGTTG TGTGTGGGA TTATGAAGCT 7560
 GAACGTCCT TCTCAATTT CACTAAGCAA GTGTGTTCT ACACTGATCT TGATAGTGA 7620
 GTTGAACAT GTTTGATA TAGTATTGCT GGCTCTTTG AGCGTTTAC TACTACAAG 7680
 GATGCAGTGC TTATTTCTAA TAACGCTGTG AAAGGGCTTA GTGCCATTAA ATTACAAT 7740
 GGCCTTTGA ATGATCTACC TGTAAGTACT GTTGGAAATA AACCTGTCAC ATGGTATAT 7800
 TATGTGCGCA AGAATGGTGA GTACGTCGA CAAATCGATA GTTACTATAC ACAGGGACCT 7860
 ACTTTGAAA CCTTCAAACC TCGTAGTACA ATGGAAGAAG ATTTTCTTAG TATGGATACT 7920
 ACACTCTTCA TCCAAAAGTA TGGTCTTGA GATTATGGT TTGAACAGT TGTATTTGA 7980
 GATGTCTTA AAATACCAT TGGTGGTATG CATCTTCTTA TATCGCAAGT GCGCCTTGA 8040
 AAAATGGGT TGTTTCCGT TCAAGAATTT ATGAATAAT CTGACAGTAC ACTGAAAAGT 8100
 TGTGTATTA CATATGCTGA TGATCCATCT TCTAAGATG TGTGCACTTA TATGGACATA 8160
 CTCTGGACG ATTTTGTGAC TATCATTAAG AGCTTAGATC TTAATGTTGT GTCCAAAGT 8220
 GTGGATGCA TTGTAGATTG TAAGGCATGG AGATGGATGT TGTGGTGTGA GAATTCACAT 8280
 ATTAACCT TCTATCCACA ACTCCAATCT GCTGAATGGA ATCCCGCTT AGCATGCCCT 8340
 ACACTGTACA AAATCCAGCG TATGTGTCTC GAACGGTGA ATCTCTACAA TTATGGTGA 8400

CAGTGGTAACT TACCTGATGG CATTACTACT AATGTCGTTA AGTATACTCA GTTGTGTCAA 8460
 TACCTTAACT CTACTACATT GTGTGTACCA CACAAAATGC GTGTATTGCA TTTAGGAGCT 8520
 GCTGGTGCAT CTGGTGTTC TCCTGGTAGT ACTGTATTAA GAAGATGGTT ACCAGATGAT 8580
 GCCATAATGG TTGATAATGA TTTGAGAGAT TACGTTTCCG ACGCAGACTT CAGTGTACA 8640
 GGTGATIGTA CTAGTCTTTA CATCGAAGAC AAGTTTGATT TGCTCGTCTC TGATTATAT 8700
 GATGGCTCCA CAAAATCAAT TGACCGTGAA AACACGTCGA AAGATGGTTT CTTTACTTAT 8760
 AATAATGGTT TCATTAAAGA GAAACTGTCA CTTGGTGGAT CTGTTGCCAT TAAAATCAG 8820
 GAATTTAGTT GGAATAAAGA TTTATATGAA TTGATTCAAA GATTGAGTA TTGGACTGTG 8880
 TTTGTACIA GTGTTAACAC GTCATCATCA GAAGGCTTTC TGATTGGTAT TAACTACTTA 8940
 GGACCATCT GTGACAAAGC AATAGTAGAT GGAATATAA TGCATGCCAA TTATATATTT 9000
 TGGAGAACT CTACAATTAT GGCTCTATCA CATACTCAG TCCTAGACAC TCCTAAATTC 9060
 AAGTGTCTTT GTAACAACGC ACTTATTGTT AATTTAAAG AAAAGAATT GAATGAAATG 9120
 GTCATTGGAT TACTAAGGAA GGTAAAGTTG CTCATTAGAA ATAATGGTAA GTTACTAAAC 9180
 TTTGGTACC ACTTCGTTAA CACACCATGA AAAATGCTG TATTTATTAC AGTTTTAATC 9240
 TTAATACTAA TTGGTAGACT CCAATTATTA GAAAGACTAT TACTTAATCA CTCTTCAAT 9300
 CTTAAACTG TCAATGACTT TAATATCTTA TATAGGAGTT TAGCAGAAAC CAGATTACTA 9360
 AAGTGGTGC TTGAGTAAT CTTCTAGTC TTAAGTAGGAT TTTGCTGCTA CAGATTGTTA 9420
 GTCACATTAA TGTAAAGCAA CCGATGTCT AAAACTGGTT TTTCCGAGGA ATTACTGGTC 9480
 ATCGCGCTGT CTAATCTGT ACAGAAATGGT AAGCACGTGT AATAGGAGGT ACAAGCAAAC 9540
 CTATTGCATA TTAGGAAGTT TAGATTTGAT TTGGCAATGC TAGATTAGT AATTAGAGA 9600
 AGTTTAAAGA TCCGCTACGA CGAGCCAACA ATGGAAGAGC TAACGTCTGG ATCTAGTGAT 9660
 TGTTTAAAT GTAAATTTGT TTGAAATTT TCCTTTTAT AGTGATACAA AAAA 9714

094503 094503

NEW CLAIMS

5 1. A defective viral genome comprising parental virus genome having viral replicase recognition signals located on ends 3' and 5', further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication.

10 2. A genome according to claim 1, comprising, additionally, the complete sequence coding for the parental virus replicase.

3. A genome according to the ^{claim 2} preceding claims, wherein the aforesaid parental virus is a coronavirus.

15 4. A genome according to the ^{claim 1} preceding claims, comprising a defective genome of a porcine, canine or feline coronavirus.

20 5. A genome according to claim 4, comprising a defective genome of the virus of transmissible gastroenteritis of pigs (TGEV).

6. A genome according to ~~any of the preceding claims~~ ^{claim 5}, wherein the aforesaid helper virus is the parental virus.

25 7. An expression vector based on a recombinant defective viral genome expressing at least one antigen capable of inducing systemic and secretory immune responses, comprising a defective viral genome according to claims 1 to 6, or its corresponding complementary DNA (cDNA), and, at least, one DNA sequence coding for an antigen capable of conferring systemic and mucosal immunity.

30 8. A vector according to claim 7, comprising more than one DNA sequence, each one of which codes for a different antigen capable of conferring systemic and mucosal immunity.

35 9. An expression vector based on a recombinant defective viral genome expressing at least one antibody which confers protection against an infectious agent, comprising a defective viral genome according to claims 1 to 6, or its corresponding complementary DNA (cDNA), and, at least, one DNA sequence coding for an antibody that confers protection against one infectious agent.

40 10. A vector according to claim 9, comprising more than one DNA sequence, each one of which codes for a different antibody that confers protection against an infectious agent.

45 11. A recombinant system based on recombinant defective viruses expressing, at least, one antigen capable of inducing systemic and mucosal immunity, comprising:

a) a recombinant expression vector based on a defective viral genome according to claims 7 or 8, containing, at least, one DNA sequence coding for an antigen capable of conferring systemic and mucosal immunity; and

b) a helper virus.

12. A system according to claim 11, wherein the aforesaid expression vector comprises more than one DNA sequence, each one of which codes for a different antigen capable of conferring systemic and mucosal immunity.

13. A system according to claim 11, comprising different expression vectors each one of which contains a different DNA sequence coding for a different antigen capable of conferring systemic and mucosal immunity.

14. A system according to any of claims 11 to 13, wherein the aforesaid helper virus is the parental virus from which the defective viral genome is derived.

15. A system according to claim 14, wherein the aforesaid helper virus provides the functional and structural proteins for the replication and encapsidation of the defective genome.

16. A system according to claim 14, wherein the aforesaid helper virus provides the structural proteins for the encapsidation of the defective genome.

17. A recombinant system based on recombinant defective viruses expressing, at least, one antibody that confers protection against an infectious agent, comprising:

a) a recombinant expression vector based on a defective viral genome according to claims 9 or 10, containing, at least, one DNA sequence coding for an antibody that confers protection against an infectious agent, and

b) a helper virus.

18. A system according to claim 17, wherein the aforesaid expression vector comprises more than one DNA sequence, each one of which codes for a different antibody conferring protection against an infectious agent.

19. A system according to claim 17, comprising different expression vectors each one of which contains a different DNA sequence coding for an antibody that confers protection against an infectious agent.

20. A system according to any of claims 17 to 19, wherein the aforesaid helper virus is the parental virus from which the defective viral genome is derived.

21. A system according to claim 20, wherein the aforesaid helper virus provides the functional and structural proteins for the replication and encapsidation of the defective genome.

22. A system according to claim 20, wherein the aforesaid helper virus provides the structural proteins for the encapsidation of the defective genome.

23. A vaccine capable of inducing protection in animals against an infectious agent, comprising a suitable quantity of a recombinant system according to any of claims 11 to 22, together with a pharmaceutically acceptable excipient.

24. A vaccine according to claim 23, wherein the aforesaid recombinant system comprises an expression vector containing a DNA sequence coding for an antigen capable of conferring systemic and mucosal immunity.

25. A vaccine according to claim 23, wherein the aforesaid recombinant system comprises an expression vector containing more than one DNA sequence, each one of which codes for a different antigen capable of conferring systemic and mucosal immunity.

26. A vaccine according to claim 23, wherein the aforesaid recombinant system comprises different expression vectors each one of which contains at least one different DNA sequence coding for a different antigen capable of conferring systemic and mucosal immunity.

27. A vaccine according to claim 23, suitable for the conferring of immunity against porcine infectious agents, wherein the recombinant system comprises at least one expression vector containing at least one DNA sequence coding for a porcine pathogen antigen.

28. A vaccine according to claim 23, suitable for the conferring of immunity against porcine infectious agents, wherein the recombinant system comprises one expression vector containing more than one DNA sequence, each one of which codes for a different porcine pathogen antigen.

29. A vaccine according to claim 23, suitable for the conferring of immunity against porcine infectious agents, wherein the recombinant system comprises different expression vectors each one of which contains at least one DNA sequence coding for a porcine pathogen antigen.

30. A vaccine according to claims 27 to 29, wherein the aforesaid porcine pathogen is selected from a group consisting essentially of: *Actinobacillus suis*, *Actinobacillus pleuropneumoniae*, *Haemophilus parasuis*, Porcine parvovirus, *Leptospira*, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Clostridium* sp., *Serpulina hyodysenteriae*, *Mycoplasma hyopneumoniae*, porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus, rotavirus, or against the pathogens causative of porcine reproductive and respiratory syndrome, Aujeszky's disease (pseudorabies), swine influenza or transmissible gastroenteritis and the etiologic agents of atrophic rhinitis and proliferative ileitis.

31. A vaccine according to claim 23, suitable for the conferring of immunity against canine infectious agents, wherein the recombinant system comprises at least one expression vector containing at least one DNA sequence coding for a canine pathogen antigen.

32. A vaccine according to claim 23, suitable for the conferring of immunity against canine infectious agents, wherein the recombinant system comprises an expression vector containing more than one DNA sequence, each one of which codes for a different canine pathogen antigen.

33. A vaccine according to claim 23, suitable for the conferring of immunity against canine infectious agents, wherein the recombinant system comprises different expression vectors each one of which contains at least one DNA sequence coding for a canine pathogen antigen.

34. A vaccine according to claims 31 to 33, wherein the aforesaid canine pathogen is selected from a group constituted essentially of: canine herpesviruses, canine adenovirus types 1 and 2, canine parvovirus types 1 and 2, canine reovirus, canine rotavirus, canine coronavirus, canine parainfluenza virus, canine influenza virus, distemper virus, rabies virus, retovirus and canine calicivirus.

35. A vaccine according to claim 23, suitable for the conferring of immunity against feline infectious agents, wherein the recombinant system comprises at least one expression vector containing at least one DNA sequence coding for a feline pathogen antigen.

36. A vaccine according to claim 23, suitable for the conferring of immunity against feline infectious agents, wherein the recombinant system comprises one expression vector containing more than one DNA sequence, each one of which codes for a feline pathogen antigen.

37. A vaccine according to claim 23, suitable for the conferring of immunity against feline infectious agents, wherein the recombinant system comprises different expression vectors each one of which contains at least one DNA sequence coding for one feline pathogen antigen.

38. A vaccine according to claims 35 to 37, wherein the aforesaid feline pathogen is selected from a group constituted essentially of: feline calicivirus, feline immunodeficiency virus, feline herpesviruses, feline panleukopenia virus, feline reovirus, feline rotavirus, feline coronavirus, feline infectious peritonitis virus, rabies virus, feline Chlamydia psittaci and feline leukemia virus.

39. A vaccine according to claim 23, wherein the aforesaid recombinant system comprises an expression vector containing a DNA sequence coding for an antibody that confers protection against an infectious agent.

40. A vaccine according to claim 23, wherein the said recombinant system comprises an expression vector containing more than one DNA sequence, each one of which codes for an antibody conferring protection against an infectious agent.

41. A vaccine according to claim 23, wherein the said recombinant system comprises different expression vectors each one of which contains at least a different DNA sequence coding for an antigen that confers protection against an infectious agent.

42. A vaccine according to claim 23, suitable for the conferring of immunity against a porcine infectious agent, wherein the recombinant system comprises at least one expression vector containing at least one DNA sequence coding for an antibody that confers protection against the aforesaid porcine infectious agent.

43. A vaccine according to claim 42, wherein the recombinant system comprises at least one expression vector containing at least one DNA sequence coding for the monoclonal antibody identified as 6A.C3 capable of neutralizing the virus of transmissible gastroenteritis of pigs (TGEV).

44. A vaccine according to claim 23, wherein the helper virus of the recombinant system comprises a coronavirus.

45. A vaccine according to claim 44, wherein the aforesaid coronavirus is selected from the group composed of porcine, canine and feline coronaviruses.

The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3' and 5', further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.




FIG. 1

2/27




FIG. 2




FIG. 3

4/27




FIG. 4

5/27




FIG. 5

6/27




FIG. 6

7/27

THER-1					
p1	p41				
mdi	mdi (ufp/ célula)				
10	10 ⁻³	10 ⁻²	10 ⁻¹	10	RNA





FIG.7

8/27



THER-1-STp46

n° de pase en células IPEC		n° de pase en células PM-2	
1	10	RNA	1 5
RNA		RNA	




FIG.8

9/27







FIG.9

10/27

A RNA genómico (28.5 kb)



B DI-B (~10.6 kb)



C DI-C (9.7 kb)




FIG.10

11/27




FIG.11

12/27

NCTTTAAAGTAAAGTGAGTGTAGCGTGGCTATATCTCTCTTTTACTTTAACTAGCCTTGTGCTAGATTTTGTCTTCGGACACCAACTC 90

GAAGTAAAGCAAATATTTGTCTTTCTATGAAATCATAGAGGACAAGCGTTGATTATTTCCATTGAGTTTGGCAATCACTCCTTGAACGG 180

M K S .

GGTTGAGCGAACGGTGCAGTAGGGTTCGTCCTATTTGTAAGTCGCCTAGTAGTAGCGAGTCCGGTTCGCCCCGTACAACGTTGGGTA 270

GACCGGGTTCGTCCTGTGATCTCCCTCGCCGGCCGCCAGGAGAATGAGTTCCAAACAATTCAAGATCCTTGTTAATGAGGACTATCAAG 360

M S S K Q F K I L V N E D Y Q

TCAACGTGCCTAGTCTTCCTATTCGTGACGTGTTACAGGAAATTAAGTACTGCTACCGTAATGGATTGAGGGCTATGTTTTGCTACCAG 450

V N Y P S L P I R D V L Q E I K Y C Y R N G F E G Y V F V P

AATACTGTCGTGACCTAGTTGATTGCCATCGTAAGGATCACTACGTGATTGGTGTCTTGGTAACGGAGTAAGTGATCTTAAACCTGTT 540

E Y C R D L V D C D R K D H Y V I G V L G N G V S D L K P V

TTCTTACCGAACCCCTCCGTCATGTTGCAAGGCTTTATTGTTAGAGCTAACTGCAATGGCGTTCTTGAGGACTTTGACCTTAAATGCTC 630

L L T E P S V M L Q G F I V R A N C N G V L E D F D L K I A

GCACTGTCAGAGGTGCCATATATGTTGATCAATACATGTGTGGTGTGATGGAAAACAGTCATTGAAGGCGATTTTAAGGACTACTTCG 720

R T V R G A I Y V D Q Y M C G A D G K P V I E G D F K D Y F

GTGATGAAGACATCATTGAATTTGAAGGAGAGGAGTACCATTGCGCTTGGACAACGTGCGCGATGAGAAACCGCTGAATCAGCAAATC 810

G D E D I I E F E G E E Y H C A W T T V R D E K P L N Q Q T

TCTTTACCATTGAGGAAATCCAATACAATCTGGACATTCCTCATAAATTGCCAAACTGTGCTACTAGACATGTAGCACCACCAGTCAAAA 900

L F T I Q E I Q Y N L D I P H K L P N C A T R H V A P P V K

FIG. 12/1

AGA A C T C T A A A T A G T T C T G T C T G A A G A T T A C A A G A G C T T T A T G A T A T C T T C G G A T C A C C C T T T A T G G G A A A T G G T G A C T G T C T T A G C A 990
K N S K I V L S E D Y K K L Y D I F G S P F H G N G D C L S
A A T G C T T T G A C A C T C T T C A T T T T A T C G C T G C T A C T C T T A G A T G C C C G T G T G G T T C T G A A A G T A C G G C G T T G G A G A T T G G A C T G G T T T T A 1080
K C F D T L H F I A A T L R C P C G S E S S G V G D W T G F
A G A C T G C C T G T T G T G G T C T T T C T G G C A A G T T A A G G G T G T C A C T T T G G G T G A T A T T A A G C C T G G T G A T G C T G T T G T C A C T A G T A T G A G C G 1170
K T A C C G L S G K V K G V T L G D I K P G D A V V T S H S
C A G G T A A G G G A G T T A A G T T C T T T G C C A A T T G T G T T C T T C A A T A T G C T G G T G A T G T T G A A G G T G T C T C C A T C T G G A A G T T A T T A A A C T T 1260
A G K G V K F F A N C V L Q Y A G D V E G V S I W K V I K T
T T A C A G T T G A T G A G A C T G T A T G C A C C C C T G G T T T T G A A G G C G A A T T G A A C G A C T T C A T C A A A C C T G A G A G C A A A T C A C T A G T T G C A T G C A 1350
F T V D E T V C T P G F E G E L N D F I K P E S K S L V A C
G C G T T A A A A G A G C A T T C A T T A C T G G T G A T A T T G A T G A T G C T G T A C A T G A T T G T A T C A T T A C A G G A A A A T T G G A T C T T A G T A C C A A C C T T T 1440
S V K R A F I T G D I D D A V H D C I I T G K L D L S T N L
T T G G T A A T G T T G G T C T A T T A T T C A A G A A G A C T C C A T G G T T T G T A C A A A A G T G T G G T G C A C T T T T T G T A C A G C G T T G G A A A G T A G T A G A G G 1530
F G N V G L L F K K T P W F V Q K C G A L F V D A W K V V E
A G C T T T G T G G T T C A C T C A C A C T T A C A T A C A A G C A A A T T T A T G A A G T T G T A G C A T C A C T T T G C A C T T C T G C T T T T A C G A T T G T A A A C T A C A 1620
E L C G S L T L T Y K Q I Y E V V A S L C T S A F T I V N Y
A G C C A C A T T T T G T G G T T C C A G A C A A T C G T G T T A A G A T C T T G T A G A C A A G T G T G T G A A A G T T C T T G T A A A A G C A T T T G A T G T T T T T A C G C 1710
K P T F V V P D N R V K D L V D K C V K V L V K A F D V F T

FIG. 12/2

14/27

AGATTATCACAATAGCTGGTATTGAGGCCAAATGCTTTGTCTGGTGCTAAATACCTGTGTTCAATAATGCACTTGTCAAACCTGTCA 1800
 Q I I T I A G I E A K C F Y L G A K Y L L F N N A L Y K L V
 GTGTTAAATCCTTGGCAAGAAGCAAAAGGGTCTTGAATGTGCATTCTTTGCTACTAGCTTGGTTGGTGCAACTGTTAATGTGACACCTA 1890
 S V K I L G K K Q K G L E C A F F A T S L Y G A T V N V T P
 AAAGAACAGAGACTGCCACTATCAGCTTGAACAAGGTTGATGATGTTGTAGCACCAGGAGAGGGTTATATCGTCATTGTTGGTGATATGG 1980
 K R T E T A T I S L N K V D D V V A P G E G Y I V I Y G D H
 CTTTCTACAAGAGTGGTGAATATTATTTTCATGATGTCTAGTCCTAATTTTGTCTTACTAACAATGTTTTTAAAGCAGTTAAAGTTCCAT 2070
 A F Y K S G E Y Y F H H S S P H F V L T N N V F K A V K V P
 CTTATGACATCGTTTATGATGTTGATAATGATACCAAAAGCAAAATGATTGCAAAACCTTGGTTCATCATTGTAACAAATACCAACTGGCA 2160
 I \longleftrightarrow II
 S Y D I V Y D V D N D T K S K H I A K L G S S F E Q I P T G
 CACAAGATCCAATTGGGTTCTGTATTGAAAATGAAGTTTGTGTTGCTGTGGTTGTTGGCTTAACAATGGTTGCATGTGCCATCGTACTT 2250
 T Q D P 1 R F C I E N E V C V Y C G C W L N H G C H C D R T
 CTATGCAGAGTTTACTGTTGATCAACTTATTAAAGCAGTGGGGTCTAGTGCAGCTGACTAGAACCCCTGCAATGGTACTGATCC 2340
 • S K L F K R V R G S S A A R L E P C N G T D P
 S H Q S F T V - D Q S Y L N E C G V L Y Q L D •
 AGACCATGTTAGTAGAGCTTTTGACATCTACAACAAGATGTTGGCTGTATTGCTAAATTCCTTAAGACGAATTGTTCAAGATTAGCAA 2430
 D H V S R A F D I Y H K D V A C I G K F L K T N C S R F R N
 TTTGGACAAACATGATGCCTACTACATTGTCAAACGTTGTACAAAGACCGTTATGGACCATGAGCAAGTCTGTTATAACGATCTTAAAGA 2520
 L D K H D A Y Y I V K R C T K T V H D H E Q V C Y N D L K D

FIG. 12/3

15/27

TTCTGGTGGTGTGCTGAGCATGACTTCTTCACATATAAAGAGGGTAGATGTGAGTTCGGTAATGTTGCACGTAGGAATCTTACAAAGTA 2610
S G A V A E H D F F T Y K E G R C E F G N V A R R N L T K Y

CACAATGATGGATCTTTGTTACGCTATCAGAAATTTTGATGAAAAGAACTGTGAAGTTCTCAAAGAAATACTCGTGACAGTAGGTGCTTG 2700
T H H D L C Y A I R N F D E K N C E V L K E I L V T V G A C

CACTGAAGAATCTTTGAAAATAAGATTGGTTTGATCCAGTTGAAAATGAAGCCATACATGAAGTTTATGCAAAACTTGGACCCATTGT 2790
T E E F F E N K D W F D P V E N E A I H E V Y A K L G P I V

AGCCAATGCTATGCTTAAATGTGTTGCTTTTTGCGATGCGATAGTGAAAAAGGCTATATAGGTGTTATAACACTTGACAACCAAGATCT 2880
A N A M L K C V A F C D A I V E K G Y I G V I T L D N Q D L

TAATGGCAATTTCTACGATTTGCGCGATTTGCTGAAGACTGCTCCGGGTTTTGGTTGCGCTTGCTTACATCATATTATTCTTATATGAT 2970
N G N F Y D F G D F V K T A P G F G C A C V T S Y Y S Y H H

GCCTTAATGGGGATGACTTCATGCTTAGACTCTGAAAACCTTTGTGAAAAGTGACATCTATGGTTCTGATTATAAGCAGTATGATTTACT 3060
P L H G H T S C L E S E N F V K S D I Y G S D Y K Q Y D L L

AGCTTATGATTTTACCGAACATAAGGAGTACCTTTTCCAAAAATACTTTAAGTACTGGGATCGCACATATCACCCAAATTGTTCTGATTG 3150
A Y D F T E H K E Y L F Q K Y F K Y W D R T Y H P N C S D C

TACTAGTGACGAGTGTATTATTTCATTGCTCTAATTTTAACACATTGTTTTCTATGACAATACCAATGACAGCTTTTGGACCACTTGTCCG 3240
T S D E C I I H C A N F N T L F S H T I P H T A F G P L V R

TAAAGTTCATATTGATGGTGTACCAGTAGTTGTTACTGCAGGTTACCATTTCAAACAACCTGGTATAGTATGGAATCTTGATGTAAAATT 3330
K V H I D G V P V V Y T A G Y H F K Q L G I V W N L D V K L

AGACACAATGAAGTTGAGCATGACTGATCTTCTTAGATTTGTCACAGATCCAACACTTCTGTAGCATCAAGCCCTGCACCTTTTAGACCA 3420
D T H K L S H T D L L R F Y T D P T L L V A S S P A L L D Q

FIG. 12/4

GCCTACTGTCTGTTTCTCCATTGCAGCTTTGAGTACTGGTATTACATATCAGACAGTAAACCAGGTCACTTTAAACAAGGATTTCTACGA 3510

R T V C F S I A A L S T G I T Y Q T V K P G H F N K D F Y D

TTTCATAACAGAGCGTGCATTCTTTGAAGAGGGATCTGAGTTAACATTAAACATTTTTCTTTGCACAGGGTGGTGAAGCTGCTATGAC 3600

F I T E R G F F E E G S E L T L K H F F F A Q G G E A A M T

AGACTTCAATTATTATCGCTACAATAGAGTCACAGTACTTGATATTTGCCAAGCTCAATTTGTTACAAAATAGTTGCCAAGTATTTTGA 3690

D F N Y Y R Y N R V T V L D I C Q A Q F V Y K I V G K Y F E

ATGTTATGACGGTGGGTGCATTAATGCTCGTGAAGTTGTTGTTACAACTATGACAAGAGTGGCTATCCTTTGAACAAATTTGGTAA 3780

C Y D G G C I N A R E V V V T N Y D K S A G Y P L N K F G K

AGCTAGACTTTACTACGAACTCTTTCATATGAAGAGCAGGATGCACTTTTGCTTTAACAAGAGAAATGTTTTACCCACAATGACTCA 3870

A R L Y Y E T L S Y E E Q D A L F A L T K R N V L P T R I Q

AATGAATTTGAAATACGCTATTTCTGGTAAGGCAAGAGCTCGTACAGTAGGAGGAGTTTCACTTCTTTCTACCATGACTACGAGACAATA 3960

M H L K Y A I S G K A R A R T Y G C Y S L L S I N I T R O Y

TCATCAGAAGCATTGAAGTCAATTGCTGCAACACGCAATGCTACTGTGGTCATTGGTTCAACCAAGTTTTATGGTGGTTGGGACAATAT 4050

H Q K H L K S I A A I R N A T Y Y I G S I K F Y G G W D N H

GCTTAAAAATTAATGCGTGATGTTGATAATGTTGTTTGATGGCATGGGACTATCCTAAGTGTGACCGTGCTTTACCTAATATGATTAG 4140

I K N I H R D Y D H C C L H G W D Y P K E D R A L P N H I R

AATGGCTTCTGCCATGATATTAGTTCTAAGCATGTTGTTGTTGTACACATAATGATAGTTCTACCGCCTCTCCAATGAGTTAGCTCA 4230

H A S A H I L G S K H V G C C T H N D R F Y R L S N E L A Q

FIG. 12/5

17/27

AGTACTCACAGAAGTTGTGCATTGCACAGGTGGTTTTTATTTAAACCTGGTGGTACAAC TAGCGGTGATGGTACTACAGCATATGCTAA 4320
 Y L T E V V H C T G G F Y F K P G G T T S G D G T T A Y A N

CTCTGCTTTTAACATCTTTCAAGCTGTTTCTGCTAATGTTAATAAGCTTTTGGGGTTGATTCAAACGCTTGAACAACGTTACAGTAA 4410
 S A F N I F Q A Y S A N V N K L L G V D S H A C N N V T V K

ATCCATACAACGTAAAATTTACGATAATTGTTATCGTAGTAGCAGCATTGATGAAGAATTTGTTGTTGAGTACTTTAGTTATTTGAGAAA 4500
 S I D R K I Y D H E Y P S S S I D E E F V Y E Y F S Y L R K

ACACTTTTCTATGATGATTTTATCTGATGATGGAGTTGTGTGCTACAACAAAGATTATGCGGATTTAGGTTATGTAGCTGACATTAATGC 4590
 H F S M H I L S D D G V Y C Y N K D Y A D L G Y V A D I W A

POLIMERASA

TTTTAAAGCAACACTTTATTACCAGAATAACGTCTTTATGTCCACTTCTAAGTGTGGTGAACACAGATCTTAGTGTGGACCACATGA 4680
 F K A T L Y Y G N N V F H S T S K C W V F P D L S Y G P H E

ATTTTGTTCACAGCATACTTGCAGATTGTTGGGCTGATGGAGACTACTATCTTCCCTATCCAGACCCGTCCAGAATTTTGTGAGCTGG 4770
 F C S D H T L Q I Y G P D G D Y Y L P Y P D P S R I L S A G

TGTGTTTGTGATGACATAGTTAAACAGACAATGTTATTATGTTAGAAGTTACGTGTCATTGGCTATTGACGCATACCCGCTCACAAA 4860
 V F V D D I Y K T D N V I H L E R Y V S L A I D A Y P L T K

ACACCCTAAGCCTGCTTATCAAAAAGTGTTTTACACTCTACTAGATTGGTTAAACATCTACAGAAAAATTTGAATGCAGGTGTTCTTGA 4950
 H P K P A Y Q K V F Y T L L D W V K H L Q K N L N A G V L D

TTCGTTTTCAGTGACAATGTTAGAGGAAGGTCAAGATAAGTTCTGAGTGAAGAGTTTACGCTAGCCTCTATGAAAAGTCCACTGTCTT 5040
 S F S V T M L E E G D D K F W S E E F Y A S L Y E K S T V L

DEDOS DE ZINC

GCAAGCTGCAGGCATGTGTGTAGTATGTGGTTCGAAACTGTACTTCGTTGTGGAGACTGTCTTAGGAGACCACTTTTATGCACGAAATG 5130
 Q A A C H C V Y C G S O T Y L R C G O L L R R P L L C T K C

FIG. 12/6

18/27

TGCTTACGACCATGTTATGGGAACAAAGCATAAATTCATTATGTCTATCACACCATATGTGTAGTTTTAATGGTTGTAATGTCAATGA 5220

A Y D H V N C T K H K F I H S I I P Y V C S F N G C N V N D

DEDOS DE ZINC

TGTTACAAAGTTGTTTTAGGTGGTCTTAGTTATTATTGTATGAACCACAAACCACAGTTGTCATTCCCCTCTGTGCTAATGGCAACGT 5310

V T K L F L G G L S Y Y C M N H K P Q L S F P L C A N G N Y

TTTTGGTCTATATAAAGTAGTGCAGTCGGCTCAGAGGCTGTTGAAGATTCAACAACTGCAGTTTCTGACTGCACTAATGTAGAAGA 5400

F G L Y K S S A V G S E A V E D F N K L A V S D W T N V E D

CTACAACTTGCTAACAATGTCAAGGAATCTCTGAAAATTTTCGCTGCTGAACTGTGAAAGCTAAGGAGGAGTCTGTAAATCTGAATA 5490

Y K L A N N Y K E S L K I F A A E T V K A K E E S V K S E Y

TGCTTATGCTGTATTAAAGGAGTTATCGGCCCTAAGGAAATTGTAATGGAAGCTTCTAAGACTAAGCCTCCACTTAACAGAAA 5580

A Y A V L K E V I G P K E I V L Q W E A S K T K P P L N R N

TTGAGTTTTCAGTGTTCAGATAAGTAAGGATACTAAAATTCATTAAGGTGAATTTGTGTTTGAGCAATCTGAGTACGGTAGTGATTC 5670

S V F T C F Q I S K D T K I Q L G E F Y F E Q S E Y G S D S

TGTTTATTACAAGAGCAGGAGTACTTACAAATTGACACCAGGTATGATTTTGTGTTGACTTCTCATAATGTGAGTCTCTTAAAGCTCC 5760

V Y Y K S T S T Y K L T P G H I F V L T S H N V S P L K A P

AATTTAGTCAACCAAGAAAAGTACAATACCATATCTAAGCTCTATCCTGTCTTTAATATAGCGGAGGCTATAATACACTGGTTCCTTA 5850

I L V N Q E K Y N T I S K L Y P V F H I A E A Y N I L V P Y

CTACCAAATGATAGGTAAGCAAAAATTTACAACCTATCCAAGGTCTCTGCTAGCGGTAAATCTCATTGTGTTATAGCTTTGGGTTTGTA 5940

Y D R T C K Q K F T T I D G P P G S G K S H C V I G L G L Y

HELICASA

FIG. 12/7

19/27

TTACCTCAGGCGAGAATAGTCTACACTGCATGTTCTCATGCGGCTGTAGACGCTTTATGTGAAAAAGCAGCCAAAACTTCAATGTTGA 6030

Y P Q A R I V Y T A E S H A A Y D A L C E K A A K H F N Y D

TAGATGTTCAAGGATAATACCTCAAAGAATCAGAGTTGATTGTTACACAGGCTTTAAGCCTAATAACACCAATGCCGAGTACTGTTTTG 6120

P C S R I I P Q R I R Y D C Y T C F K P N N T N A D Y L F C

TACTGTTAATGCTCTACCAGAAGCAAGTTGTGACATTGTTGTAGTTGATGAGGTCTCTATGTGTACTAATTATGATCTTAGTGTCATAAA 6210

T V N A L P E A S C D I V V V D E V S H C T N Y D L S V I N

TAGCCGACTGAGTTACAAACATATTGTTTATGTTGGAGACCCACAGCAGCTACCAGCTCCTAGAACTTTGATTAATAAGGGTGACTTCA 6300

S R L S Y K H I V Y V G D P Q Q L P A P R T L I N K G V L Q

ACCGCAGGATTACAATGTTGTAACCAAAAGAATGTGCACACTAGGACCTGATGTCTTTTGCATAAATGTTACAGGTGCCGAGTCGAAAT 6390

P Q D Y N V V T K R H C T L G P D V F L H K C Y R C P A E I

TGTTAAACAGTCTCTGCACTTGTGTTATGAAAATAAATTTGTACCTGTCAACCAGAATCAAAGCAGTGCTTCAAAATGTTTGTTAAAGG 6480

Y K T Y S A L V Y E N K F V P V N P E S K Q C F K H F V K G

TCAGATTGAGTCTAAGTCTTCTATAAACAACAAGCAACTAGAGGTTGTCAAGGCCCTTTTAGCACATAATCCAAAATGGCGTAA 6570

Q I Q I E S N S S I N N K Q L E V V K A F L A H N P K W R K

AGCTGTTTTCATCTCACCTATAATAGTCAAAATTATGTTGCTCGGCGTCTTCTTGTTTGCAAACGCAAACTGTGGATTCCGCTCAGGG 6660

A V F I S P Y N S Q N Y V A R R L L G L Q T Q T V D S A Q G

TAGTGAGTATGATTACGTCATCTAGCTGCTCTGAAGATTTTAAATCCTGCTGCAATTCACGATGTGGTAATCCAAAAGGCATCCGTTGT 6750

S E Y D Y V I .

II ← I → III

GCTACAACACCAATACCATGGTTTTGTTATGATCGTGATCCTATTAATAACAATGTTAGATGTCTGATTATGACTATATCGGTACATCGT 6840

FIG. 12/8

20/27

CAAATGAATGGTCTTATGTTATTTTGGAACTGTAATGTAGACATGTACCCAGAGTTTTCAATTGTTTGTAGATTGATACTCCCACTCGC 6930
TCTAAATTGCTTTAGAAGTTGTAATGGTGGTGCATTGTATGTTAATAACCATGCTTCCACACACCAGCTTATGATAGAAGAGCTTTT 7020
GCTAAGCTTAAACCTATGCCATTCTTTTACTATGATGATAGTAATTGTGAACCTGTTGATGGGCAACCTAATTATGTACCACCTTAAGTCA 7110
AATGTTTGCATAACAAAATGCAACATTGGTGGTGTCTGTCTGCAAGAAGCATGCTGCTCTTTACAGAGCGTATGTTGAGGATTACAACATT 7200
TTTATGCAGGCTGGTTTTACAATATGGTGTCTCTCAAACTTTGACACCTATATGCTTTGGCATGGTTTTGTTAATAGCAAAGCACITCAG 7290
AGTCTAGAAAATGTGGCTTTTAAATGTCTGTTAAGAAAGGTGCCTTCACCGGTTTAAAAGGTGACTTACCAACTGCTGTTATTGCTGACAAA 7380
ATAATGGTAAGAGATGGACCTACTGACAAATGTATTTTACAAATAAGACTAGTTTACCTACAAATGTAGCTTTTGAGTTATATGCAAAA 7470
CGCAAACCTTGGACTCACACCTCCATTAACAATACTTAGGAATTTAGGTGTTGTGCGCAACATATAAGTTTGTGTTGTTGGGATTATGAAGCT 7560
GAACGTCCTTTCTCAAATTTCACTAAGCAAGTGTGTTCTTACACTGATCTTGATAGTGAAGTTGTAACATGTTTTGATAATAGTATTGCT 7650
GGCTCTTTTGAGCGTTTTACTACTACAAGAGATGCAGTGCTTATTTCTAATAACGCTGTGAAAGGGCTTAGTGCCATTAAATTACAATAT 7740
GGCCTTTTGAATGATCTACCTGTAAGTACTGTTGGAATAAACCTGTCACATGCTATATCTATGTGCGCAAGAATGCTGAGTACGTCGAA 7830
CAAATCGATAGTTACTATACACAGGAGCTACTTTTGAACCTTCAAACCTCGTAGTACAATGGAAGAAGATTTTCTTAGTATGGATACT 7920
ACACTCTTCATCCAAAAGTATGCTCTTGAGGATTATGGTTTTGAACACGTTGTATTTGGAGATGTCTCTAAACTACCATTTGGTGGTATG 8010
CATCTTCTTATATCGCAAGTGGCCTTGCAAAAATGGGTTTGTTCCTGTTCAAGAATTTATGAATAATTCTGACAGTACACTGAAAAGT 8100
TGTGTATTACATATGCTGATGATCCATCTTCTAAGAATGTGTGCACCTATATGGACATACTCTTGACGATTTTGTGACTATCATTAAAG 8190
AGCTTAGATCTTAATGTTGTGTCCAAAGTTGTGGATGTCATTGTAGATTGTAAGGCATGGAGATGGATGTTGTGGTGTGAGAATTCACAT 8280
ATTAAACCTTCTATCCACAACCTCAATCTGCTGAATGGAATCCCGCTATAGCATGCCTACACTGTACAAAATCCAGCGTATGTGTCTC 8370
GAACGGTGAATCTCTACAATTATGGTGACAAGTGAATTACCTGATGGCATTACTACTAATGTCGTTAAGTATACTCAGTTGTGTCAA 8460
TACCTTAACACTACTACATTGTGTGTACCACACAAAATGCGTGTATTGCATTTAGGAGCTGCTGGTGCATCTGGTGTGCTCCTGCTAGT 8550
ACTGTATTAAGAAGATGGTTACCAGATGATCCATATTGGTTGATAATGATTTGAGAGATTACGTTTCCGACGCAGACTTCAGTGTTACA 8640

FIG. 12/9

GGTGATTGCTAGTCTTTACATCGAAGACAAGTTTGATTGCTCGTCTCTGATTTATATGATGGCTCCACAAAATCAATTGACGGTGAA 8730
 AACACGTCGAAAGATGGTTTCTTTACTTATATTAATGGTTTCATTAAAGAGAAAACGTCACTTGGTGGATCTGTTGCCATTAAAATCAGC 8820
 GAATTTAGTTGGAATAAGATTTATATGAATTGATTCAAAGATTTGAGTATTGGACTGTGTTTTGTACAAGTGTTAACACGTCATCATCA 8910
 GAAGGCTTTCTGATTGGTATTAACACTTAGGACCATACTGTGACAAAGCAATAGTAGATGGAATATAATGCATGCCAATTATATATT 9000
 TGGAGAACTCTACAATTATGGCTCTATCATAACTCAGTCCTAGACACTCCTAAATCAAGTGTGTTGTAACAACGCACCTTATTGTT 9090
 AATTTAAAGAAAAAGAATTGAATGAAATGGTCATTGGATTACTAAGGAAGGGTAAGTTGCTCATTAGAAATAATGGTAAGTTACTAAAC 9180
 TTTGGTAACCACTTCGTTAACACACCAATGAAAAAATGCTGTATTTATTACAGTTTTAATCTTACTACTAATTGGTAGACTCCAATTATTA 9270
 III ← I → IV
 H K K C C I Y Y S F N L T T N W .
 GAAAGACTATTACTTAATCACTCTTTCAATCTTAAACTGTCAATGACTTTAATATCTTATATAGGAGTTTAGCAGAAACCAGATTACTA 9360
 AAAGTGGTCTTCGAGTAATCTTTCTAGTCTTACTAGGATTTTGTCTGCTACAGATTGTTAGTCACATTAATGTAAGGCAACCCGATGTCT 9450
 AAAACTGGTTTTTCCGAGGAATTACTGGTCATCGCGCTGTCTACTCTTGTACAGAATGGTAAGCACGTGTAATAGGAGGTACAAGCAACC 9540
 CTATTGCATATTAGGAAGTTTAGATTTGATTTGGCAATGCTAGATTTAGTAATTTAGAGAAGTTTAAAGATCCGCTACGACGAGCCAACA 9630
 ATGGAAGAGCTAACGTCTGGATCTAGTGATTGTTTAAATGTAAAATTTGTTGAAAATTTTCCTTTTGATAGTGATACAAAAAA 9714

FIG. 12/10

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) e^{-x^2} dx = \frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) e^{-x^2} dx$




FIG. 13






FIG.16




FIG. 17




FIG.18

Docket No. ACY-33261

Patent

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Gale F. Matthews	Reg. No. <u>32,269</u>
Milagros A. Cepeda	Reg. No. <u>33,365</u>
Darryl L. Webster	Reg. No. <u>34,276</u>
Alan M. Gordon	Reg. No. <u>30,637</u>
Elizabeth M. Barnhard	Reg. No. <u>31,088</u>
Andrea Walsh	Reg. No. <u>34,988</u>

☐ Attached as part of this declaration and power of attorney is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE AND TELEPHONE CALLS TO:

Milagros A. Cepeda
American Home Products Corporation
Patent Law Department
One Campus Drive
Parsippany, NJ 07054
Tel. No. (973) 683-2124

Docket No. ACY-33261
Patent

DECLARATION

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

1-00 Full name of SOLE OR FIRST INVENTOR Luis Enjuanes Sanchez

Inventor's Signature [Signature] Date 7 - Sept. 98
Country of Citizenship Spain
Residence C/Camino Nuevo, 113, 28100 Alcombendas, Madrid, Spain ESX
Post Office Address (Same)

2-00 Full name of SECOND JOINT INVENTOR Juan Plana Duran

Inventor's Signature [Signature] Date 4 - Sept. - 98
Country of Citizenship Spain
Residence Ctra. Camprodón, Poligono Industrial "La Riba", VALL DE BIANYA-OTLOT ESX
(Gerona) Spain
Post Office Address (Same)

3-00 Full name of THIRD JOINT INVENTOR Sara Alonso Villanueva

Inventor's Signature [Signature] Date 7/1x/98
Country of Citizenship Spain
Residence Autónomo, 62, 48012 - Bilbao (Vizcaya), Spain ESX
Post Office Address (Same)

4-00 Full name of FOURTH JOINT INVENTOR M^aLuisa Ballesteros Jarreno

Inventor's Signature [Signature] Date 7/1x/98
Country of Citizenship Spain
Residence C/Sánchez Vera, 7 - 3^oB, 16002 - Cuenca, Spain ESX
Post Office Address (Same)

Docket No. ACY-33261
Patent

COMBINED DECLARATION AND POWER OF ATTORNEY
(Original, Design, Supplemental, Divisional, Continuation, CIP)

As the below named inventor, I hereby declare that:

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

**VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR
USE IN THE FORMULATION OF VACCINES.**

SPECIFICATION IDENTIFICATION

the specification of which: (complete (a), (b), or (c))

- (a) ☐ is attached hereto.
(b) ☐ was filed on as
 ☐ Serial Number
 ☐ Express Mail No. , as Serial Number not yet known
(c) ☒ was described and claimed in PCT International Application No.
PCT/ES97/00059 filed on March 12, 1997 and as amended under PCT Article 19
on (if any).

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37 CFR 1.56(a).

Declare.ACY-33261

Page 1 of 8

20250903 14:55:00

Docket No. ACY-33261
Patent

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventors certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate of any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

- (d) ☐ No such applications have been filed.
(e) ☒ Such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. claimed priority, check item (e), enter the details below and make the priority claim.

Earliest Foreign Application(s), if any, filed within 12 months (6 months for Design) prior to this U.S. Application

Country	Application No.	Date of Filing (Day, Month, Year)	Priority Claimed 35 USC 119
Spain	9600620	14-03-1996	Yes

All Foreign Application(s), if any, Filed More Than 12 Months
(6 Months for Design) Prior to This U.S. Application)

Docket No. ACY-33261

Patent

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. § 119(E))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER**FILING DATE**

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. 120

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT International filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 USC 120

U.S. Applications		Status (Check One)		
U.S. Applications	U.S. Filing Date	Patented	Pending	Abandoned
1.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PCT Applications Designating U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NO. ASSIGNED (if any)		
3. PCT/ES97/00059	March 12, 1997	NONE		
4.				

Declare.ACY-33261

Page 3 of 8

0915003 091498

Docket No. ACY-33261
PatentSIGNATURE(S)5-00 Full name of FIFTH JOINT INVENTOR Joaquin Castilla CastrillonInventor's Signature [Signature] Date 7/9/98
Country of Citizenship Spain
Residence Marqués de la Valdavia, 94. Escalera 2, 4ºA, 28100-Alcobendas, Madrid, Spain ESX
Post Office Address (Same)6-00 Full name of SIXTH JOINT INVENTOR José Manuel Gonzalez MartinezInventor's Signature [Signature] Date 7-9-98
Country of Citizenship Spain
Residence Vicente Medina, 28. Miranda, 30319 - Cartagena, Murcia, Spain ESX
Post Office Address (Same)1
7-00 Full name of SEVENTH JOINT INVENTOR Ander Izeta ParmesanInventor's Signature [Signature] Date 7-9-98
Country of Citizenship Spain
Residence Pº de los Arbustos, 18, 5º, 20009 - San Sebastian, Guipúzcoa, Spain ESX
Post Office Address (Same)8-00 Full name of EIGHTH JOINT INVENTOR Ana Mendez ZunzuneguiInventor's Signature [Signature] Date 7-9-98
Country of Citizenship Spain
Residence Gran Via, 170, 36210 - Vigo, Pontevedra, Spain ESX
Post Office Address (Same)

Docket No. ACY-33261
PatentSIGNATURE(S)9-00 Full name of NINTH JOINT INVENTOR Maria Muntion SaenzInventor's Signature [Signature] Date 7/9/1998
Country of Citizenship Spain
Residence Avenida Pamplona, 25 - 6º B., 31010 - Pamplona Navarra, Spain ES
Post Office Address (Same)10-00 Full name of TENTH JOINT INVENTOR Zoltán PenzesInventor's Signature [Signature] Date 7/9/1998
Country of Citizenship Spain
Residence Isla de Ons, 6, 4º, 28035, Madrid, Spain ESX
Post Office Address (Same)11-00 Full name of ELEVENTH JOINT INVENTOR José Manuel Sanchez MorgadoInventor's Signature [Signature] Date 7/9/98
Country of Citizenship Spain
Residence Avenida Portugal, 62, 3º, 28933, Mostoles, Madrid, Spain ESX
Post Office Address (Same)12-00 Full name of TWELTH JOINT INVENTOR Carlos Miguel Sanchez SanchezInventor's Signature [Signature] Date 7/9/98
Country of Citizenship Spain
Residence C/Villajoyosa, 94, Bajo, 28041, Madrid, Spain ESX
Post Office Address (Same)

Docket No. ACY-33261
Patent

SIGNATURE(S)

13-00 Full name of THIRTEENTH JOINT INVENTOR Cristina Smerdou Picazo

Inventor's Signature Cristina Smerdou Date Sep 7th, 98

Country of Citizenship Spain

Residence Avda. Brasilla, 37, 28028, Madrid, Spain ESX

Post Office Address (Same)

14-00 Full name of FOURTEENTH JOINT INVENTOR Isabel Sola Gurpegui

Inventor's Signature Isabel Sola Date Sep 7th, 98

Country of Citizenship Spain

Residence Ctra. Estrella, 61, 31570, San Adrian, Navarra, Spain ESX

Post Office Address (Same)

SCANNED 1